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Abstract 
The introduction of CRISPR/Cas9 simplified genetic, genomic, transcriptional, and 
epigenomic engineering approaches. CRISPR is a bipartite system, which means that while 
the molecular effect is defined by the utilized Cas9 variant, its targeting is determined by 
small RNAs molecules, the guide RNAs. Because of the bipartite nature, CRISPR enables to 
target multiple sites in single cells at once, which is however dependent on gRNA 
multiplexing. Here I applied CRISPR in three different projects.  
Firstly, I created STAgR (String Assembly gRNA cloning), a single step method, which 
allows the generation of multiplexed gRNA vectors in a time- and cost- efficient manner.  
Secondly, I aimed to combine this technique with novel dCas9-based methyltransferation 
tools to manipulate chromatin marks identified by epigenome-wide association studies, which 
occur in Alzheimer’s disease patients. I discovered, however, that all tested cell and tissue 
types, are already hypermethylated on these sites indicating no causal relationship. 
Thirdly, I deployed the STAgR method to manipulate multiple transcription factors aiming to 
induce transcriptional programs of certain subtype specific neurons using dCas9-based 
transcriptional activator tools. Current approaches of reprogramming remain insufficient, 
likely, because they are based on the activation of a limited number of cell identity factors. I 
was able to confirm the induction of various transcription factors following my strategy while 
the reprogramming in vivo analysis of cell identity reprogramming is still ongoing.  
Zusammenfassung 
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Zusammenfassung 
CRISPR/Cas9 bietet zum ersten Mal eine einfache Möglichkeit zur genetischen, 
genomischen, transkriptionellen und epigenomischen Manipulation. Das CRISPR System 
besteht aus zwei verschiedenen Komponenten. Während der molekulare Effekt durch die 
verwendete Cas9-Variante definiert ist, wird der Ort des Effekts durch kleine RNA Moleküle, 
die sogenannten guideRNAs, bestimmt. Im Rahmen dieser Arbeit wurden drei verschiedene 
Projekte bearbeitet. Zum einen, entwickelte ich STAgR (String Assembly gRNA cloning), 
eine Methode, welche es ermöglicht, in einem einzigen Schritt multiplexe gRNA Vektoren 
kosten- und zeiteffizient zu generieren.  
Zum anderen sollte diese Methode in Kombination mit neuartigen dCas9-basierten 
Methyltransferasewerkzeugen benutzt werden um gezielt bestimmte DNA Methylierung zu 
manipulieren. Diese Modifikationen wurden durch epigenomweite Assoziationsstudien 
identifiziert, da eine signifikante Veränderung in Alzheimer Patienten berichtet wurde. Jedoch 
tragen alle getesteten Zell- und Gewebetypen an diesen Stellen bereits hohe 
Methylierungslevel, weswegen ein kausaler Zusammenhang unwahrscheinlich ist. 
In dem letzten Teil dieser Arbeit wurde die STAgR- Methode benutzt um gleichzeitig die 
Expression von mehreren Transkriptionsfaktoren zu manipulieren Aktuelle experimentelle 
Reprogrammierungsansätze basieren auf der Überexpression von Zellidentitätsfaktoren. Dies 
führt zwar zu einer Transdifferenzierung zum gewünschten Zelltyp, jedoch bleibt eine 
Spezifizierung aus. Da dies wahrscheinlich auf einer begrenzten Anzahl von 
Identitätsfaktoren basiert, soll mit Hilfe von dCas9- basierten Transkriptionsaktivatoren ganze 
Transkriptionsprogramme manipuliert werden, welche einen neuronalen Subtyp spezifizieren. 
Ich konnte die Expression verschiedener Transkriptionsfaktoren induzieren, die 
Reprogrammierung von sutypspezifischen Neuronen in vivo ist jedoch noch nicht 
abgeschlossen. 
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A. Introduction 
1. Cell states and identity 
The concept that all organisms are assembled from similar units of organization is now more 
than 180 years old. In 1838, Theodor Schwann and Matthias Schleiden postulated their theory 
of cells being the building blocks and basic units for structure, physiology, and organization 
in every living being. This theory has foreshadowed some of the greatest paradigms of 
modern biology, such as Darwin’s theory of evolution or Mendel’s laws of inheritance. 
Today, we know that those building blocks are not only structural units providing frameworks 
for the organs, the cells are rather the minimal physiological unit of the body (Harris 1999). 
Each of the individual cells in a human body (and there are more than 10
13
 (Bianconi et al. 
2013)) can adopt a specialized physiological state which is important and necessary for the 
individual cellular functions. Until now, these different cell types are mostly classified by 
their appearance, their functional role in the system or their capability to give rise to other, 
different cell types. The fact that each body contains various different cellular types creates 
one of the most interesting scientific conundrums (Vickaryous and Hall 2006). All cells in a 
human body originate from a single cell, the zygote (Mitalipov and Wolf 2009). This means 
that all cells (with few exceptions) contain the same genetic material and therefore the 
information to be in any of the cellular states. How the phenotypic and functional diversity of 
cells in a body is formed out of the same genome is still being investigated. Nearly 80 years 
ago, Conrad Hal Waddington contributed a concept which helps to understand how this might 
be established. In his publication in 1957 he writes  that “we certainly need to remember that 
between genotype and phenotype, and connecting them to each other, there lies a whole 
complex of developmental processes” (Waddington 1957), suggesting a layer of information 
beyond genetics. He continues: “It is convenient to have a name for this complex: 
‘epigenotype’ seems suitable”, defining the beginning of epigenetic research. He visualized 
this idea in his so called “epigenetic landscape” (Fig. 1A) (Waddington 2012). The 
development and differentiation of the zygote is portrayed as a marble rolling down a hill. 
The marble has different paths to choose from and the further the marble progresses down the 
hill, the more committed the cell is to a terminally differentiated state. The landscape shaping 
components are cell fate-determining factors - transcription factors - which initiate specific 
transcriptional programs. These programs define the path of the marble and therefore 
predetermine which fate the stem cell, once it is committed, pursues (Fig. 1A). Once a cell 
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commits to a certain fate it undergoes a lasting and non- reversible epigenetic change; the cell 
remains in this committed state even if the initial trigger is no longer present.  
1.1 Master transcription factors, cell identity and reprogramming  
By now it is known that the “landscapers” Waddington was describing are a class of genes, 
known as transcription factors. These factors are proteins which recognize 5 to 15 bp long 
DNA motifs often located at gene promoters or cis- regulatory elements such as enhancers 
(Whyte et al. 2013). Through this interaction and the binding of other co- activators as well as 
co- repressors, transcription factors regulate the expression of specific genes by recruiting the 
transcriptional machinery to a gene promoter (Spitz and Furlong 2012). If a single 
transcription factor orchestrates a whole cellular fate by activating either other transcription 
factors or regulating a number of fate determining targets, it is considered a master 
transcription factor. As these factors possess a potency to force an entire specific cellular fate 
their expression pattern can be highly specific (Vaquerizas et al. 2009). Moreover single 
factors or a combination are seen to determine and protect cell identities and lineage choices 
(Morris and Daley 2013). Some of these factors are even potent enough to influence the 
identity of a terminally differentiated cell (Fig. 1B). The first factor which was shown to 
possess such reprogramming capacity was the basic helix loop helix transcription factor 
MYOD. In 1987, it was shown that when overexpressed in terminally differentiated 
fibroblasts MYOD pushed the cells beyond their natural potency and out of their “dead- end 
valley” in the epigenetic landscape to reprogram them into contracting myocytes, a muscle 
identity (Davis, Weintraub, and Lassar 1987). Yet it is not only possible to push a cell from 
one dead- end valley to another, but to directly reverse the path the marble took down the 
epigenetic landscape (Fig. 1C). Yamanaka and colleagues reversed differentiation to induce a 
pluripotent cell by the overexpression of four different transcription factors, OCT4, KLF4, 
SOX2 and cMYC in embryonic as well as adult fibroblasts (Takahashi and Yamanaka 2006). 
These experiments lead to a large series of transcription factor mediated reprogramming. 
Through overexpression of master transcription factors, it is possible to generate a large 
number of different cellular identities out of various somatic cells. Like this, e.g. 
cardiomyocytes (Ieda et al. 2010), beta cells (Q. Zhou et al. 2008) or even neurons (Berninger 
et al. 2007; Masserdotti, Gascon, and Götz 2016; Vierbuchen et al. 2010) were generated, 
using different starting cells. Even if this kind of reprogramming is based on overexpression 
of artificial transgenes, these transcription factors induce a new permanent epigenetic and 
transcriptional state which is maintained even after removal or silencing of said transgenes 
(Woltjen et al. 2009). Amongst master transcription factors there are certain subclasses in 
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reprogramming potency. There are factors which enable a reversion of differentiation, factors 
which can induce alternative options for differentiation and factors which enable a “dead- end 
valley” to “dead- end valley” transition in a process called direct reprogramming (Fig. 1C).  
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Fig. 1│ The Waddington Epigenetic Landscape. A Overview over the Waddington Landscape. Waddington 
described important terms like plasticity, potency, lineages in form of narrowing valleys. The different slopes are 
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created by underlying factors: chromatin regulates genes, genes regulate gene expression and this gene 
expression defines the valleys. B Visualization of induced pluripotency, dedifferentiation, transdifferentiation, 
and direct conversion of cells. C Visual description of the theory what a master transcription factor or a 
reprogramming factor does to the Waddington Landscape. Modified after License date: Nov. 14, 2019; License 
number: 4707660543298.  
1.2 Cortex development and neuronal subtype specification 
The mammalian neocortex is a complex structure, which can be subdivided into six different 
layers. These cortical layers are composed of three distinct mature cell types: neurons, 
astroglia and oligodendroglia (Peters and Jones 1984). Each of those layers harbor different 
subtypes of these main cellular classes. Neurons can be further subdivided into two main 
classes. These are inhibitory GABAergic interneurons which connect locally to surrounding 
targets and excitatory glutamatergic projection neurons whose axonal extensions extend 
intracortically, subcortically or even sub-cerebrally (Molyneaux et al. 2007). Neurons can be 
also classified based on the laminar position of their cellular bodies, morphology of soma or 
dendrites, and their axonal connectivity (Jabaudon 2017; Lodato, Shetty, and Arlotta 2015). 
This immense heterogeneity already begins to emerge early during development. After the 
expansion of the dorsolateral wall of the rostral neural tube, the ventricular zone forms above 
the ventricle and later the subventricular zone. Progenitor cells, which emerge from these 
structures, then give rise to the numerous subtypes of projection neurons of the different 
neocortical layers. This happens during embryonic days E11.5 until E17.5 in a spatially and 
temporally tightly controlled process (Caviness and Takahashi 1995). The six-layered 
neocortex is generated in an “inside- out fashion” as later born neurons of the superficial 
layers have to migrate past earlier- born deep- layer neurons (Fame, MacDonald, and Macklis 
2011). These superficial layers mostly consist of neurons derived from basal progenitors from 
the subventricular zone (Tarabykin et al. 2001). Overall, the mammalian neocortex shows a 
substantial neuronal diversity, also within, but especially between the different layers. One of 
these cellular subtypes is the one of callosal projection neurons (CPN), a class of neurons, 
which can be further subdivided into deep layer CPN or CPN of the superficial layer. While 
deep layer CPN show long- distance dual projection axons, their counterpart of the superficial 
layers participates in the local circuitry within cortical columns (Fame, MacDonald, and 
Macklis 2011). There is a number of factors which define the development of upper layer 
neurons and more specifically CPN. So for example, SATB2 (Special AT- rich sequence- 
binding protein 2), was shown to be critical as a molecular regulator during CPN specification 
(Alcamo et al. 2008; Britanova et al. 2008). This DNA binding transcription factor acts as an 
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anchor for chromatin remodelers and modifiers like HDAC1 (Baranek et al. 2012; Britanova 
et al. 2008). Like this, it supports repression of CTIP2 and actively suppresses the subcortical 
projection neuron fate by indirectly controlling axonal outgrowth and fasciculation (Arlotta et 
al. 2005; Baranek et al. 2012; Britanova et al. 2008). CUX2 (Cut- like homebox 2) is a 
member of the Cut family of transcription factors and was shown to take part in regulation of 
dendrite branching, spine development and synapse formation in layer II to III neurons in the 
cerebral cortex (Cubelos et al. 2010). MEF2C, short for Myocyte enhancer factor- 2C, is a 
transcription factor which was found to positively regulate transcriptional activities of bHLH 
factors during neurogenic differentiation (B. L. Black et al. 1996; Mao and Nadal-Ginard 
1996). Through temporal and spatial expression patterns during neuronal differentiation it was 
postulated that this transcription factor could be important for development of cortical 
architecture and neuronal maturation (Heidenreich and Linseman 2004; Leifer et al. 1993) and 
was also found to be essential for axonal outgrowth of subcerebral projection neurons 
(MacDonough 2016). CUX1 was shown to be complementary to CUX2 and as well an 
intrinsic regulator of dendrite branching, spine development, and synapse formation in layer II 
to III (Cubelos et al. 2010; Nieto et al. 2004). TLE2 (Transducin- like enhancer protein 2) is 
an interaction partner of FoxG1 and was shown to specify telencephalon development (Roth 
et al. 2010). LHX2 (LIM homebox 2) was shown to have crucial roles in progenitor 
specification, which then give rise to neocortical projection neurons (Molyneaux et al. 2007). 
It is also postulated that LHX2 may provide a balance of proliferation and differentiation in 
cortical progenitors (Chou and O’Leary 2013). BHLHB5 has been demonstrated to draw 
sharp areal boundaries in the developing cortex and to orchestrate projection neurons to gain 
specific phenotypic traits (Joshi et al. 2008). BRN2, a POU- domain transcriptional regulator, 
was found to be expressed in superficial cortical layers and essential for subtype specific 
differentiation into pyramidal neurons as well as proper cortical lamination and neuronal 
migration (McEvilly et al. 2002; Sugitani et al. 2002). NURR1 is a transcription factor which 
is linked to control of dopaminergic identity and was recently shown to be able to induce 
reprogrammed neurons with laminar specific hallmarks (Kadkhodaei et al. 2009, 1, 2013; 
Mattugini et al. 2019). Heterogeneity and subtype specificity present special challenges for 
neural replacement therapies. If neurons are lost by traumatic brain injury or 
neurodegenerative diseases, it is likely not sufficient to replace them with any neuronal cell 
(Heinrich, Spagnoli, and Berninger 2015; Kriks et al. 2011). Lost subtypes have to be 
replaced by subtypes, to be able to form lost neuronal circuits. Recent insights into the control 
of cell identity indicated that any cell might be compelled to become a neuron once specific 
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transcriptional programs have been triggered (Lu, Bradley, and Zhang 2014). The genetic 
introduction of exogenous copies of reprogramming factors engineered for constitutive 
expression through the addition of viral elements has proven to be a powerful approach to 
generate new neurons, both in vitro and in vivo (Gascón et al. 2015; Gohlke et al. 2008; Guo 
et al. 2014; Giacomo Masserdotti et al. 2015). Such a change in cell identity can be enforced 
through the expression of master cell-fate-determining regulators like Neurogenin, ASCL1, 
MYT1L, BRN1/2, NEUROD1/4 or PAX6 (Berninger et al. 2007; Heinrich et al. 2010; 
Vierbuchen et al. 2010; Heins et al. 2002). Nonetheless, established master reprogramming 
factors (like ASCL1, NGN2 and NEUROD1 and 4, MYT1L and BRN2) are potentially, even 
in combinations, insufficient to drive subtype- specific neuronal fates and ensure full cellular 
maturation. The set of master transcription factors (specifically NEUROD1 and NEUROD4) 
should therefore be extended and supplemented by factors which were thought to take 
influence on transcriptional programs which could define specific cellular subtypes. 
Nowadays tremendous amounts of sequencing data provide a basis for an idea which factors 
could play a role in subtype specific differentiation. Also, knockout studies conducted earlier 
give ideas about what factors play important roles for neuronal differentiation and subtype 
specification. As I aimed for trans-differentiation to callosal projection neurons, the following 
factors, which were chosen as candidates were SATB2, CUX2, MEF2C, CUX1, LHX2, 
BHLHB5, BRN2, NURR1, and TLE2.  
2. Epigenetic gene regulation 
In eukaryotes, chromatin exists of DNA which is wrapped around small proteins, the so called 
histones. There are a number of chromatin modifying enzymes, which add or remove small 
chemical residues from histone tails or directly from DNA bases (Tessarz and Kouzarides 
2014). Some of these modifications have been shown to influence chromatin accessibility and 
therefore control transcription to a certain extent. However the correlation of changes in 
chromatin marks and the resulting change in gene expression patterns does not necessarily 
imply a causation (Bultmann and Stricker 2018). Even if various studies have shown that 
these modifications and resulting chromatin features can have influence on a transcriptomic 
level, it is still difficult to link these changes to a phenotypic outcome. Despite the fact that 
chromatin can be modified in at least 100 different ways, only of a few of these modifications 
are studied in respect to gene activation and silencing which will be introduced briefly in the 
following.  
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2.1 Chromatin Modifications 
2.1.1 DNA Methylation 
The simplest yet the most prominent chromatin modification is the methylation of the 
nucleobase cytosine to 5- methylcytosine (5mC) (Lister et al. 2009). The modification itself 
was already discovered in 1948 (Hotchkiss 1948), whereas the proposal that it is stably 
inherited, influences gene expression and therefore affects cellular differentiation took another 
25 years (Holliday and Pugh 1975; Riggs 1975). In mammals nearly all of the present DNA 
methylation occurs in CpG dinucleotides, but still can exist in any context of the genome 
(Lister et al. 2009). The machinery which is in control of this modification is by now also 
known in detail. A combination of the DNA methyltransferases DNMT3A and DNMT3B is 
responsible for de novo methylation of unmodified cytosine residues to 5mC (Okano et al. 
1999) whereas DNMT1 ensures that DNA methylation which was present before replication 
is inherited to both strands afterwards (E. Li, Bestor, and Jaenisch 1992). Methylation patterns 
of promoter regions are often associated with the alteration of chromatin density and therefore 
the accessibility for transcription factor binding, impairing expression of subsequent genes 
(Cedar and Bergman 2009). Early studies dating back to the beginning of the nineties showed 
that hypermethylation of CpG islands in X-chromosome inactivation (XCI) results in active 
silencing of a whole chromosome, to guarantee dosage compensation of X-encoded genes in 
female cells (Duncan et al. 2018; Lock et al. 1986; Singer-Sam et al. 1990). In contrast to 
these mechanistic properties of DNA methylation, it was shown that CpG islands in the 
promoter region of endoderm development master regulator FOXA2 are highly methylated in 
expressing tissues, suggesting the exact opposite (Bahar Halpern, Vana, and Walker 2014). 
This shows that in reality the property of epigenetic regulation of DNA methylation might be 
far more complex than previously thought.  
 
Fig. 2│ Overview of chemical species of DNA methylation. DNMT enzymes de novo methylate the 5C 
residue of cytosine which can then subsequently be de- methylated by TET enzymes. Species which are 
generated in the process are 5hmC, 5fC and 5caC. Modified after S. H. Stricker and Götz 2018. 
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While the term “DNA methylation” often mainly refers to 5mC, we today know that there are 
some more DNA modifications based on methylation and even de- methylation. In addition to 
cytosine, adenine can be a target for methylation as well to form N6- methyladenine (6mA) 
(T. P. Wu et al. 2016). The same cytosine residue as in 5mC can be similarly methylated at 
another position, to form N3- methylcytosine (3mC) (Sadakierska-Chudy, Kostrzewa, and 
Filip 2015). As de- methylation of 5mC occurs via three subsequent enzymatic reactions it 
brings forth three additional derivates (Fig. 2) (Booth, Raiber, and Balasubramanian 2015). 
The de- methylation machinery, to which the family of the ten- eleven translocation enzymes 
(TET1, TET2 and TET3) belongs, catalyzes the oxidation of 5mC to C5- 
hydroxymethylcytosine (5hmC). To fully demethylate the cytosine residue, there are two 
more steps necessary; C5-formylcytosine (5fC) and C5-carboxylcytosine (5caC) before 
thymine DNA glycosylase (TDG) actively removes the mark (He et al. 2011; Ito et al. 2011; 
Yu et al. 2015; G. Zhang et al. 2015). There is some evidence that these derivates are not only 
steps in between the removal of an epigenetic mark but rather can have regulatory functions 
too. So for example the transcription factor UHRF1 recognizes 5hmC and actively needs this 
modification to bind its motif (Arita et al. 2008; Fang et al. 2016; Frauer et al. 2011). This 
suggests a functional role for 5hmC as UHRF1 was shown to bear key roles in maintaining 
DNA methylation during an early onset of development and hence regulating later stages of 
neuronal differentiation (Ramesh et al. 2016). Even if the last two derivates of TET- mediated 
de- methylation occur very rarely in the genome, efforts have been made to investigate 
epigenetic readers of 5fC and 5aC (Ito et al. 2011). 5fC and 5caC, mainly appearing in early 
embryos, embryonic stem cells and neuronal tissues, was shown to enable binding of factors 
involved in transcription and chromatin regulation, more specifically forkhead box domain 
transcription factors and parts of the NuRD complex (Iurlaro et al. 2013; Spruijt et al. 2013).  
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2.1.2 Histone marks 
The function and regulatory properties of chromatin is not only limited to direct DNA 
modifications, but is thought to hold an additional layer of information through the histone 
code. Here the main protein component of chromatin, the so called histones provide a far 
bigger basis for different chemical modifications, set or removed by numerous chromatin 
modifying enzymes (Tessarz and Kouzarides 2014). All histones, except the linker histone 
H1, are assembled into octamers containing two copies of the core units H2A, H2B, H3 and 
H4 which are entangled by exactly 147 bp of DNA, forming the so called nucleosomes 
(Richmond and Davey 2003). To date, 12 different modifications have been found at 130 
different amino acid residues, mostly part of the N- terminal tail of histones (Tan et al. 2011; 
Tessarz and Kouzarides 2014) These chemical modifications, like acetylation, 
phosphorylation or methylation, are thought to influence virtually all processes involving 
chromatin, e.g. transcription, replication and DNA repair. This is thought to be done by 
directly influencing the accessibility of binding sites for regulatory factors on DNA through 
changes of the physical properties of chromatin or by forming a whole new layer of signal 
transduction (Strahl and Allis 2000). Even if there is still a need for elucidating specific roles 
and functions of distinct chromatin modifications, certain residues were shown to correlate 
with certain transcriptional states. Trimethylation of lysine 4 on histone H3 (H3K4me3) and 
acetylation of lysine residues K9 and K27 of the very same subunit tend to occur at the 
promoter region of genes which are actively transcribed (Fig. 3) (Bernstein et al. 2005; 
Heintzman et al. 2007; Kim et al. 2005; Santos-Rosa et al. 2002). Marks which are 
characteristic for active gene transcription can not only be found in promoter regions, but are 
also elevated in gene bodies as well as cis- regulatory elements, such as enhancers. So are 
active gene bodies marked with trimethylation of two different lysine residues, namely 
H3K79 and H3K36 and enhancers with high levels of H3K4 monomethylation and H3K27 
acetylation (Barski et al. 2007; Heintzman et al. 2007, 2009). In contrast to these active 
marks, trimethylation of H3K27 and H3K9 was shown to be enriched in repressive chromatin 
states during development (Fig. 3) (Boyer et al. 2006).  
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Fig. 3│How chromatin marks may influence gene activity. Specific chromatin marks can potentially have 
influence on gene activity. Typical marks for an inactive state are DNA methylation, H2K9me3 and H3K27me3 
at transcription start sites of genes. Chromatin compaction can also be an indicator for inactive gene regions. 
Markers for active genes can be H2K27ac or H3K4me at cis- regulatory elements such as enhancers or H3K9ac 
and H3K4me3 at transcription start sites. H3K26me3 and H3K79me3 can be found at gene bodies of active 
genes.  
Nonetheless, even if the presence or absence of chromatin marks (DNA Methylation and 
histone modifications) can be associated with transcriptional activity, there is still a need to 
establish whether changes in chromatin marks only correlate with transcriptional changes or if 
there is a causal connection.  
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3. CRISPR/Cas9 – controllable transcription factor and chromatin modifier 
Advances in “omics”-methods have characterized the epigenome and its potential influence 
on transcriptional programs based on correlations. Yet, it remained difficult to prove a causal 
connection between epigenetic features and transcriptional control. Early studies which aimed 
for proof of this connection did so by altering chromatin marks on a global basis. This was 
done by mutation of either chromatin modifying enzymes, robbing the cell of its modifying 
machinery (Boonsanay et al. 2016) or the histone residue itself, by making a modification 
impossible on a global scale (Funato et al. 2014). However, this cannot provide insight into 
distinct functions of individual chromatin marks at specific sites.  
With the discovery of ZFNs (Zinc Finger Nucleases) and TALENs (Transcription Activator- 
like Effectors) it for the first time became possible to bind and modify specific parts of the 
genome as well as the epigenome with a high degree of specificity (Miller et al. 2011; 
Moscou and Bogdanove 2009; Urnov et al. 2005; F. Zhang et al. 2011). However, changing 
target sites required a complete re- design of these artificial transcription factors which is why 
they never were fully embraced by the scientific community (Adli 2018). With the dawn of 
the CRISPR/ Cas9 technology, this changed dramatically. CRISPR stands for clustered 
regularly interspaced short palindromic repeat and was first discovered in Escherichia coli in 
1987 (Ishino et al. 1987). It was found to be part of a complex defense mechanism of the 
bacterial immune system (Makarova et al. 2006) and once the mechanistic functions of the 
separate parts were unraveled, CRISPR/Cas9 was engineered to become one of the most 
significant biotechnological tools for genome editing of the early 21
st
 century (Gasiunas et al. 
2012; Jinek et al. 2012). This bipartite system is based on an endonuclease (Cas9) which can 
be targeted to any specific part of the genome, by programming it with a short RNA, the so 
called guideRNA (gRNA). The gRNAs are composed of a 20 bp protospacer motif, which 
defines the targeting site by sequence complementarity, and a scaffold sequence, which forms 
a complex with the Cas9 protein. If the 20 bp targeting site is followed by a so- called 
protospacer adjacent motif (PAM- an NGG motif in case of S. pyogenes Cas9), stable Cas9 
binding can be established and double strand breaks introduced, enabling various options for 
genome editing (Fig. 4A/B) (Anders et al. 2014; Sternberg et al. 2014).  
The removal of the nuclease activity of the nuclease Cas9 by point mutations in the coding 
sequence resulted in a versatile and most flexible tool for epigenomic research, namely the 
catalytically inactive dead Cas9 (dCas9) (Qi et al. 2013). It is possible to target nearly every 
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part of the genome and use dCas9 as a shuttle for specific chromatin modifying enzymes or 
artificial transcription factors opening up numerous possibilities to manipulate the epigenome.  
3.1 Transcriptional Engineering – targeted manipulation of gene expression 
One very prominent way to exploit dCas9 is its use in manipulating expression of endogenous 
genes. As the rather big protein of dCas9 establishes a reliable interaction with DNA it can be 
used to spatially hinder the transcriptional machinery (such as transcription factors and RNA 
Polymerase II) to assemble at the transcription start site and therefore interfere with 
endogenous expression of a target gene (Qi et al. 2013). To exploit the shuttle function of 
dCas9 to its fullest one can fuse different effector domains to the N-terminus of the 
catalytically dead endonuclease. Like this, one can repress expression of target genes by 
targeting the transcription start sites with strong repressor complexes such as the Kruppel- 
associated Box (KRAB) (Gilbert et al. 2013).  
However, dCas9 fusion constructs can not only be used to block transcription, but be 
exploited to do rather the opposite, as targeting the transcriptional start site of genes with 
strong transcriptional activators can result in robust gene induction. The first generation of 
these fusion constructs was based on viral or non- viral transcription factor domains, like the 
16- amino- acid- long transactivator domain (VP16) derived from the Herpes simplex virus. 
Targeting this domain to the transcriptional start site of a gene can result in a solid gene 
induction. This is accomplished by utilizing the domains original function, namely the 
interaction with a variety of transcription factors and recruitment of key components of the 
transcriptional machinery, including RNA Pol II (Y. Liu et al. 1999). A multitude of different 
alterations of these artificial transcription factors have emerged over the years. As the number 
of VP16 repeats has been shown to correlate with transcriptional activator capacity (Sadowski 
et al. 1988; Seipel, Georgiev, and Schaffner 1992), potent multimers of the transactivator 
domain have been generated. This includes the most prominent version with four tandem 
repeats, VP64, and also the eight- (VP128) and twelve- copy (VP192) version (Balboa et al. 
2015; Cheng et al. 2013; Maeder et al. 2013; Mali et al. 2013). An additional variation is the 
so called butterfly dCas9, which was designed to carry two copies of VP64 on both protein 
ends, further increasing its activator capability (J. B. Black et al. 2016; Chakraborty et al. 
2014; Gao et al. 2014). 
The field of transcriptional engineering is still evolving. Combinations of VP64 and other 
transactivator domains have been proven to be most potent. VPR, which is a tripartite 
transactivator complex, artificially pushes the levels of endogenous gene expression to nearly 
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physiological levels. It is composed of VP64 fused to two additional factors, namely P65 and 
Rta (Chavez et al. 2015). Like VP64, Rta is transactivator domain derived from a virus 
(Epstein- Bar virus), whereas P65 is a domain from the mammalian NF- κB transcription 
factor (Hardwick et al. 1992; Seipel, Georgiev, and Schaffner 1992). Direct fusion constructs 
are only one way to recruit transactivator domains to target sites: dCas9 has been equipped 
with protein tags, which then help to recruit multiple effector domains which are fused to the 
tag’s counterpart. In that way, effector domains can be accumulated at e.g. transcriptional start 
sites to establish solid endogenous gene induction (Tanenbaum et al. 2014; H. Zhou et al. 
2018). Additionally, the RNA scaffold of gRNAs has been engineered to harbor two 
recognition sites for the MCP protein, forming a stable protein RNA interaction. Once 
equipped with transactivator domains like P65 or HSF1, this can be used to accumulate 
effector domains at a Cas9 marked target site and results in highly efficient gene induction 
(Konermann et al. 2014a; Zalatan et al. 2015).  
Utilizing this technique for targeting endogenous versions of e.g. transcription factors, harbors 
massive potential, even in cellular reprogramming. It was shown that targeted activation by 
dCas9’VPR of the two pro- neural factors NGN2 and NEUROD1 in iPSCs can trigger neural 
differentiation (Chavez et al. 2015). BRN2, ASCL1 and MYT1L, the so called BAM factors, 
were shown to yield a high capacity to direct reprogram mouse embryonic fibroblasts into 
neurons when overexpressed as transgenes (Vierbuchen et al. 2010). The same holds true for 
endogenous gene activation, as butterfly dCas9’VP64 shows direct conversion capability from 
MEFs to neurons when targeted to the BAM loci simultaneously (J. B. Black et al. 2016). 
Cells could not only be trans- differentiated, it was also shown that a solid de-differentiation 
can be achieved by targeting the endogenous loci of OCT4 and SOX2 with a dCas9SunTag 
enhanced system, to induce pluripotency (P. Liu et al. 2018). Neural progenitors already 
committed to a glial fate could also be dedifferentiated by targeted SOX1 activation, and got 
back a lost differentiation potential to a neuronal fate (Baumann et al. 2019).  
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Fig. 4│Possible utilizations of CRISPR. A The gRNA forms a complex with the Cas9 protein. This RNA 
protein complex then scans the genomic DNA for the complementary sequence of the N20 protospacer, followed 
by the for binding necessary Protospacer Adjacent Motif (PAM). B CRISPR based tools provide a tremendous 
amount of possibilities. WTCas9 can be used to induce base- specific mutations, large scale deletions or for 
specific gene targeting. Mutations of the enzymatic domain of Cas9 have generated a dead version of the protein. 
The options this tool can be used in, have been subdivided into two groups: Epigenomic engineering and 
transcriptional engineering. In Epigenomic engineering dCas9 is used to shuttle chromatin modifier to specific 
places in the genome to set or remove for example DNA methylation or specific chromatin marks. 
Transcriptional Engineering summarizes the manipulation of transcription of endogenous genes by targeting 
their promoter region with activators or repressors.  
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3.2 Epigenomic Engineering – targeted manipulation of chromatin marks 
Trying to unravel the function of chromatin modifications does not necessarily answer the 
question of causality. The introduction of dCas9 opened up a tremendous amount of 
opportunities to directly target exactly this kind of questions. Tools generated for epigenomic 
engineering are based on dCas9 shuttles which enable a site- specific manipulation of 
chromatin marks by targeting loci with chromatin modifying enzymes or their catalytical 
domains. This has been done for a variety of complex chromatin modification but also for the 
simplest one, DNA methylation, providing first evidence of a potential direct effect of DNA 
methylation on transcriptional regulation. Various fusion constructs of dCas9 to DNMT 
enzymes, like the mammalian de novo methyltransferase DNMT3A (or its catalytical domain) 
or the prokaryotic CG methyltransferase M.SSSI/MQ1 have been reported to induce de novo 
methylation of unmethylated CpGs (Amabile et al. 2016; Lei et al. 2017a; Vojta et al. 2016a; 
Ziller et al. 2018). Higher methylation rates could be achieved by combining DNMT3A with 
its co- factor DNMT3L (Stepper et al. 2017a). De novo methylation capacity appears to be 
highly dependent on the target locus, as methylation efficiency varies from 2 to up 80% 
depending on the target gene (Huang et al. 2017; Jurkowski, Ravichandran, and Stepper 2015; 
Pflueger et al. 2018). These epigenomic engineering tools provide the possibility to draw a 
link between specific epigenomic- and transcriptional changes. This however requires a 
target- specificity as potential off- target effects of these systems won’t allow unraveling the 
functional consequences of specific DNA methylation. As shown by Pflueger et al. many of 
the utilized dCas9 fusion methylation tools show high off- target DNA methylation, which 
could be improved by accumulating DNMT3A via a dCas9 Sun-tag system (Pflueger et al. 
2018). Nonetheless, even a catalytically dead version of DNMT3A leads to some DNA 
methylation, suggesting that the endogenous DNMT machinery is recruited resulting in 
unwanted CpG modification. This clearly shows the importance to further develop more 
advanced methylation tools.  
Nonetheless, engineered methylation resulted in subsequent transcriptional reduction of target 
genes, providing first evidence that chromatin modifications can potentially modulate 
transcription (Amabile et al. 2016; Huang et al. 2017; X. S. Liu et al. 2016a). Targeted 
methylation could counteract elevated levels of synuclein alpha protein (SNCA) in human 
iPSCs derived from dopaminergic neurons from Parkinson’s disease patients (Kantor et al. 
2018). In another example DNA methylation of multiple target sites in primary breast cells 
could prevent senescence and drive hyper- proliferation, a phenotype typically seen in breast 
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cancer development, suggesting DNA hypermethylation not only as a hallmark of cancer, but 
as a driving force (Saunderson et al. 2017).  
Of course similar systems have been developed with de- methylation machinery (Anton and 
Bultmann 2017; Morita et al. 2016; Okada et al. 2017; Xu et al. 2016). Quite similar to the 
methylation studies, the effects are rather variable. The molecular consequences vary from 
10% to full de- methylation (Baumann et al. 2019; Choudhury et al. 2016; Okada et al. 2017). 
The transcriptional consequences of de- methylation range from rather mild induction 
(Choudhury et al. 2016; Morita et al. 2016) to strong gene activation (X. S. Liu et al. 2016a; 
X. Shawn Liu et al. 2018). Different in vitro and in vivo studies could also link de- 
methylation of disease relevant genes to phenotypic changes. The de- methylation of tumor 
suppressor genes is for example sufficient to trigger proliferation phenotypes (Choudhury et 
al. 2016) or de- methylating of the FMR1 locus in affected neurons is able to rescue disease 
hallmarks of the fragile X syndrome (X. Shawn Liu et al. 2018).  
These systems can even be applied for manipulation of the histone code. When deployed to 
promoter regions and distal enhancers, a dCas9 fusion construct with the histone 
acetyltransferase p300 for instance could activate transcription in MYOD and OCT4, to levels 
which were even higher than those achieved by transcriptional engineering (Hilton et al. 
2015). Trimethylation of H3K4 could restore the expression levels of silenced genes in 
various cancerous cell types by targeting the promoter regions with histone methyltransferase 
PRDM9 (Cano-Rodriguez et al. 2016). In contrast to this dCas9’LSD1 helped to characterize 
and verify various enhancer regions, as de- methylation of target histones resulted in gene 
silencing (Kearns et al. 2015; Mendenhall et al. 2013). 
In most cases of epigenomic engineering, modification of chromatin marks were followed by 
transcriptional changes. This however differs strongly between the distinct modifications, 
suggesting that not every single mark harbors the same regulatory potential. However, this is 
apparently also highly dependent on the target locus which means that specific marks could 
maybe only regulate a specific subset of sites.  
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3.3 gRNA multiplexing  
A lot of different approaches in genomic, transcriptional and epigenomic engineering suggest 
that it is often not enough to target just a single site. As CRISPR is bipartite, the only 
limitation which is set in terms of multiple targeting is the number of gRNAs which are 
provided for the machinery. Of course, one could just simply mix a number of similar gRNA 
expression vectors prior to deployment, however this does not ensure that cells will (A) get all 
gRNAs simultaneously and (B) in stoichiometric amounts.  
To overcome this bottleneck, different techniques have been developed to generate vectors 
which harbor more than one gRNA expression cassette, so called multiplexed gRNA vectors. 
Due to the small size of one single gRNA expression cassette it is possible to create vectors 
with up to 14 different expression cassettes in a row (Peterson et al. 2016). Generation of 
these vectors however is often based on large synthesized oligonucleotides. There therefore is 
a need for methods to generate these kinds of vectors faster and especially cheaper. Protocols 
which were introduced for generation of multiplexed gRNA vectors were based on classical 
cloning with restriction and ligation (Dow et al. 2015; J. F. Li et al. 2013; Yan et al. 2016), 
isocaudomer based cloning (C. Wang et al. 2015) or Golden Gate Cloning and variants 
(Kabadi et al. 2014; Sakuma et al. 2015a; Vazquez-Vilar et al. 2016). Other gRNA 
multiplexed systems rely on the transcription of a precursor RNA driven by one single 
promoter. The precursor transcript is then further processed to release single gRNAs. This can 
be achieved by different measures, but nearly all of the systems rely on ribonucleases which 
excise linker sequences or cut between gRNA sequences. These linkers can be tRNA 
sequences which are recognized and excised by endogenous RNases (K. Xie, Minkenberg, 
and Yang 2015) or small hairpin/micro RNA motifs which are cut by the ribonuclease 
DROSHA (C. Xie et al. 2017; Yan et al. 2016), releasing flanking gRNAs into the cell.  
In the process of this PhD thesis, I established a novel gRNA multiplexing assembly protocol. 
String Assembly gRNA cloning (STAgR) is exploiting several aspects of Gibson cloning and 
based on generation of small building blocks by simple overhang PCRs. These are then 
subsequently assembled in one single overnight reaction. This technique provides an easy, 
cost-effective and efficient way to multiplex gRNA vectors and was unmatched in its 
flexibility and customizability. With the establishment of the STAgR technique, I found a 
solid basis for extending the transcriptional and epigenetic engineering tools.  
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4. Epigenetic regulation in Alzheimer’s disease 
Alzheimer is a neurodegenerative disease in which amongst other factors and physiological 
symptoms neuritic amyloid plaques and tangles of intracellular hyperphosphorylated tau can 
cause synaptic dysfunction and neuronal cell death which leads to a decrease of cerebral 
matter (Selkoe 2012). In Alzheimer‘s Disease there are many hints that there is an influence 
of environmental factors and therefore an epigenetic influence on disease development. The 
disease undoubtedly has a genetic component, but this component seems only rarely to be the 
cause of the burden. Genome wide association studies (GWAS) have identified genetic 
mutations which patients have in common and could therefore be a driving force of disease 
development. They unravelled mutations in genes like APP (Goate et al. 1991; P. H. St 
George-Hyslop et al. 1987), PSEN1 (Sherrington et al. 1995; P. St George-Hyslop et al. 1992; 
Van Broeckhoven et al. 1992) and PSEN2 (Sherrington et al. 1996) which can lead to an early 
onset of the disease (before 65 years). However this familiar inherited variant only seems to 
occur in a very small percentage (5%) of all Alzheimer’s cases. The other 95% seem to be a 
sporadic form where aberrations in the gene of apolipoprotein E- ε4 (APOE) lead to a higher 
risk to develop this late-onset form (after 65 years) (Diniz et al. 2017; R. Zhao et al. 2017). 
Nonetheless only 25% of people having these mutations then really develop the disease, 
whereas another 50% don‘t even carry aberrant genetic information but develop it anyway 
(Van Cauwenberghe, Van Broeckhoven, and Sleegers 2016).  
Epigenetic modifications, the chemical marks attached to the DNA or histones, are integrating 
environmental and intrinsic signals in the cell (Jaenisch and Bird 2003). Signalling pathways, 
environmental effects and cellular memories are all imprinted in the complex patterns of 
chromatin marks, which individually can potentially regulate expression of specific genes and 
taken together constitute the epigenome. Some of these chromatin mark patterns are transitory 
and change dynamically during development, described by Waddington in his epigenetic 
landscape. In contrast to this some states can be established stably and even be inherited. 
However, the described changes cannot only occur during development but there is also 
evidence that during various diseases an abnormal distribution of epigenetic signals can occur. 
Therefore an epigenetic influence on disease development seems likely. So for example leads 
the miss- regulation of the clearly epigenetic controlled mechanism of epithelial to 
mesenchymal transition to a hijacking of a normal cellular program to support cancer 
progression and metastasis (Acloque et al. 2009). Wrong cellular epigenetic signals can also 
lead to a false distribution up to an absence of for example T cells in the severe combined 
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immunodeficiency syndrome (R. H. Buckley 2004; Rebecca H. Buckley 2004). Lastly a large 
body of work has shown that in many diseases, including the neurodegenerative diseases 
Alzheimer’s (AD) and Parkinson’s (PD), abnormal chromatin marks do occur and therefore 
abnormal physiological cellular states can be adopted (Ammal Kaidery, Tarannum, and 
Thomas 2013; Mastroeni et al. 2011; Urdinguio, Sanchez-Mut, and Esteller 2009).  
The exact mechanisms of Alzheimer’s disease are still unknown and the disease burden 
cannot be solely explained by genetic factors. Therefore studies have been conducted to look 
into epigenetic differences which could be linked to disease development. Among the best 
profiled chromatin modifications in AD is DNA methylation, an especially stable epigenetic 
mark. The promoter region of the APP gene for instance was found to be hypermethylated in 
Alzheimer cases (Tohgi, Utsugisawa, Nagane, Yoshimura, Genda, et al. 1999; Tohgi, 
Utsugisawa, Nagane, Yoshimura, Ukitsu, et al. 1999). A neuron specific methylome analysis 
of post mortem brain samples revealed a hypomethylation of the promoter of the gene BRCA1 
which was consistent with a significant overexpression of the same gene (Mano et al. 2017). 
Overexpressed and mislocalized BRCA1 seems to contribute to a decline of genomic integrity 
under the burden of accumulated amyloid ß (a characteristic for Alzheimer’s pathology) in 
several mouse models. This phenomenon goes hand in hand with promoter hypomethylation, 
suggesting (A) a contribution of BRCA1 to AD pathogenesis and (B) an underlying 
epigenetic mechanism based on promoter methylation which misregulated BRCA1 expression 
(Mano et al. 2017). Recently, studies have revealed that some differentially methylated 
positions seem to be potent biomarkers for AD progression. CpG islands of the APOE gene 
seem to be hypomethylated in AD cases in the frontal lobe more specific in the non- neuronal 
cells of post mortem patient samples (Foraker et al. 2015; Tulloch et al. 2018). Furthermore it 
has been suggested that an increase of methylation of the gene of Phosphatidylinositol binding 
clathrin assembly protein (PICALM) is connected to cognitive decline during AD progression 
(Mercorio et al. 2018). Numerous studies have tried to link distinct methylation patterns to 
Alzheimer’s disease. Overall, it appears that there is a global decrease in 5mC in post-mortem 
AD brain samples, be it in cortical neurons or more generally in the hippocampus, entorhinal 
cortex and cerebellum (Chouliaras et al. 2013; Condliffe et al. 2014; Mastroeni et al. 2010). 
Two independent epigenome-wide association studies (EWAS) have recently used large 
cohorts of pre-symptomatic AD patients and control groups to collect brain samples and to 
determine DNA methylation changes (De Jager et al. 2014; Lunnon et al. 2014). Importantly, 
both studies revealed identical disease associated DNA methylation marks (close to the genes 
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RHBDF2, RPL13, C10orf54– CDH23 and ANK1) (Fig. 5). Moreover, those epigenetic marks 
emerge early during pathogenesis, correlate to a loss of gene expression, and occur so 
frequently that a role in the disease, either by spontaneous occurrence (as epimutations) or as 
an epigenetic memory of environmental factors, seems plausible. However, our knowledge 
about the effects of disease associated chromatin marks is very limited. So far, functional 
insights could be exclusively obtained by indirect approaches (e.g. by genetic manipulation) 
and was largely limited to developmental marks and animal models (like for example in 
genomic imprinting (Latos et al. 2009; Stefan H Stricker et al. 2008). As direct manipulation 
of individual chromatin marks (in human cells) remained impossible until very recently, it is 
still enigmatic to which extend disease associated chromatin marks contribute to the disease, 
how they operate and how they could be counteracted. 
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Fig. 5│Highly methylated loci identified in two independent EWAS. 5 single CpGs sites were identified in 
two independent EWA studies and were found to be highly methylated in Alzheimer’s Disease patients, 
compared to control groups. ANK1, RPL13, and RHBDF2 are known to be linked to PTK2B, a gene already 
identified to be AD- associated. Modified after Lord and Cruchaga 2014. 
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5. Scientific aims 
Utilizing CRISPR/Cas9 in transcriptional as well as epigenomic engineering opens up a 
tremendous amount of scientific avenues. The aims of my studies concentrate mostly on tool 
generation for the fast progressing CRISPR field and biological questions which are 
simplified by the generated tools. CRISPR/Cas9 also helps to tackle more classical scientific 
approaches from a different point of view. Direct neuronal reprogramming is possible through 
transgenic introduction of constitutively active master transcription factor genes. The 
spectacular success of direct reprogramming approaches should, however, not obscure the fact 
that these methods are currently far from perfect. Direct neuronal reprogramming is at 
present, rather inefficient, as only a fraction of cells appropriately switches cell identity while 
others remain undifferentiated or stuck in intermediate stages (Coutts and Keirstead 2008); 
toxic, as a significant proportion of cells die after virus- mediated expression of cell fate 
determining transcription factors, both in vitro and vivo approaches (Gascón et al. 2016) and 
incomplete, as cells do not fully differentiate into mature and adequate neuronal subtypes 
(Gascón et al. 2016). By activating the endogenous gene copies of master regulators by 
transcriptional engineering, I aim to overcome certain difficulties and limitations the 
reprogramming field is facing. One huge limitation is the number of master regulator genes 
that can be introduced at once. This could potentially be the reason for insufficient and 
incomplete maturation during artificial trans-differentiation. Toxicities connected to 
unphysiological expression levels caused by viral promoters (especially in vivo) might also be 
a consequence of inadequate and immature cell states. By exploiting one of the biggest 
advantages of the CRISPR system, namely the possibility to target multiple genes 
simultaneously, I aimed to orchestrate the trans- differentiation process to gain neuronal 
subtype specificity of upper layer callosal projection neurons. Here cells should be primed by 
the neuronal pioneering factor NEUROD1 as it was shown that this factor can convert 
reactive astrocytes to glutamatergic neurons in vitro and in vivo (Guo et al. 2014). This should 
be uses as a basis to then further push the cells into a specific subtype, targeting multiple 
factors at once using dCas9 based activators. 
One additional aim is to manipulate DNA methylation marks occurring in Alzheimer’s 
patients by epigenomic engineering. Like this potential disease relevant marks should be 
recreated at five different loci, which had previously been shown to be associated with 
Alzheimer’s disease (De Jager et al. 2014; Lunnon et al. 2014). With these manipulations, I 
set out to validate a contribution of pathological chromatin marks to the disease. Previous 
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studies have been shown that current methylation tools based on dCas9 still show off- target 
effects. Therefore I aim for deploying amongst the classical ones, novel methylation tools, 
generated during this study. I generated fusion constructs with viral (M.CVIPI from the 
Chlorella virus (Buryanov and Shevchuk 2005)) and plantal (DNA (cytosine-5)-
methyltransferase 1A (DNM1A) and DNA (cytosine-5)- methyltransferase DRM2 (DRM2) 
methyltransferases which were optimized for human expression. Advantages gained could be 
better controllability, independence of host factor interactions, and depending on the type of 
methyltransferase, the investigation of effects of non-human methylation patterns. 
All approaches in transcriptional as well as epigenomic engineering attempted during this 
thesis required a reliable gRNA multiplexing system. Therefore, I first set out to establish 
such a system.  
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B Results 
1. Generating Multiplexed gRNA vectors with String Assembly gRNA Cloning 
(STAgR) 
 
This chapter contains text and data that were published in:  
Breunig CT, Durovic T, Neuner AM, Baumann V, Wiesbeck MF, Köferle A, Götz M, 
Ninkovic J, Stricker SH: “One step generation of customizable gRNA vectors for 
multiplex CRISPR approaches through string assembly gRNA cloning (STAgR)”. PLoS 
One 13, e0196015 (2018).(C. T. Breunig et al. 2018a) 
Breunig CT, Neuner AM, Giehrl-Schwab J, Wurst W, Götz M, Stricker SH: “A 
Customizable Protocol for String Assembly gRNA Cloning (STAgR)”  J. Vis. Exp. (142), 
e58556, doi:10.3791/58556 (2018).(C. T. Breunig et al. 2018b) 
CRISPR experiments are highly dependent on the target information provided by gRNAs. 
Some paradigms do not only require delivery of one but multiple gRNAs to one single cell 
reliably. An ideal protocol to generate multiplexed gRNA vectors would be simple, fast and 
cost-effective and could be conducted reliably while maintaining a high degree of 
customizability. In order to meet these requirements, I developed String assembly gRNA 
cloning (STAgR). STAgR makes use of the Gibson assembly method (Gibson et al. 2009). 
The Gibson method is based on a witty combination of three different enzymes. An 
exonuclease removes nucleotides from the 5’-end of double- stranded but linearized DNA. 
Complementary single stranded DNA regions can then anneal to each other. Phusion DNA 
polymerase fills then the gaps and TAQ DNA ligase covalently joins the annealed 
complementary DNA fragments, by removing the individual nicks. The STAgR method 
allows the assembly of multiple gRNA expression cassettes into an expression vector in a 
single overnight reaction by using the N20 gRNA sequences as complementary DNA 
sequences. PCR-amplified building blocks are generated from a short DNA template, the 
string, which is composed of a gRNA scaffold sequence of choice, a transcriptional stop 
signal (poly dT) and a Pol III promoter (Fig. 6). By including the gRNA targeting sequence 
(N20) as primer overhangs during the PCR amplification of the string sequence, the building 
blocks for Gibson assembly can be generated from one universal template. By exploiting this, 
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STAgR is not only simple, but remains highly customizable because various combinations of 
different strings and backbones are possible (Fig. 7B).  
 
Fig. 6│The STAgR string. To generate building blocks for multiplexed gRNA vectors the string has to be 
amplified with overhang primers, adding the N20 targeting information via PCR as a Gibson overhang. The 
string consists of a gRNA scaffold, a poly- T transcriptional stop and a Pol III promoter 
1.1 Optimization of STAgR conditions 
The protocol was tested by setting up a strategy for a gRNA expression plasmid with four 
different individual gRNAs, targeting the promoter region of the gene Ascl1. All expression 
cassettes were driven by the human U6 promoter, terminated by the classical spCas9 gRNA 
scaffold and a poly-T sequence. The individual PCR conditions for gRNA building blocks 
and vectors were determined by gradient PCR and can be found in the Materials and Methods 
section. Following successful PCR amplification of the strings as well as a vector using 
overhang primers (Fig. 8A/B), the DNA fragments were assembled in a Gibson reaction. This 
enzymatic assembly is sensitive to two different factors: the ratio of individual DNA 
fragments in the reaction mix and the incubation time. Both parameters where tested 
individually: Equimolar amounts of three gRNA string-based building blocks were added to 
the vector in either a three-fold or five-fold excess or the vector in a three-fold excess relative 
to the amount of used inserts (Fig. 8E). The Gibson assembly reaction was stopped after 20, 
30, 40, and 60 minutes. Reactions were transformed into bacteria and colonies screened by 
colony PCR (Fig. 8C/D). This strategy was used to both rapidly screen bacterial clones for the 
desired assembly product and gauge the efficiencies of the assembly under the different 
conditions. Quantifications in Figure 8E show the percentage of different obtained gRNA 
subsets in dependence on the ratio of educts and reaction time. As expected, the nature of the 
assembly products varied with the ratio of the individual components and time. I found that 
gRNA building blocks as well as vectors should be combined in an equimolar ratio and 
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incubation times should not exceed 40 minutes at 50°C. Using these parameters, 34% of all 
clones contained the desired four gRNA cassettes. With these results, I could show that 
STAgR can efficiently assemble multiple gRNA expression cassettes under the optimized 
conditions (Fig. 8D/E). Hence, these parameters were used in all subsequent experiments 
(Fig. 8F). Sanger sequencing was used to confirm the seamless assembly of desired 
multiplexed gRNA expression vectors designed in silico. Colony PCR also revealed that 
STAgR clones which did not contain all gRNA expression cassettes showed bands which 
represented subsets of different gRNA expression cassette numbers. Sanger sequencing 
revealed that these clones indeed lack one or more gRNA expression cassettes without a 
further cloning scar, breakage points or sequence repetitions. Each STAgR reaction therefore 
not only spawns gRNA vectors with the intended number of gRNA cassettes, but additionally 
yields a subset of different combinations and number of gRNA expression units which can be 
used for additional experiments.  
B Results 
 
36 
 
 
Fig. 7│Overview of the STAgR method. A String Assembly gRNA cloning is a 3 step cloning method to 
generate multiplexed gRNA vectors. The overhangs which are implemented via PCR are not only the target 
information of the gRNAs but also serve as homology sequence for Gibson assembly. B STAgR was engineered 
to be highly customizable. The choice of string and backbone provide a wide variety of possibilities to form the 
perfect vector for any experiment. Parts of this figure were modified and taken from C. T. Breunig et al. 2018b.  
B Results 
 
37 
 
 
Fig. 8│Establishment and optimization of STAgR. A PCR amplification of string with primers lacking 
overhangs (lane 1) and with overhangs and therefore the target information added (lanes 2- 4). PCR products 
were analyzed on a 1.5% agarose gel, stained with SYBR safe. B STAgR PCR of two vectors (lane 1 and 2) and 
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four insert building blocks with the N20 added (lane 3 to 6). PCR fragments were analyzed on a 1.5% agarose 
gel, stained with SYBR safe. C Overview of the colony PCR. Obtained clones are picked with a pipette tip and 
biological material is transferred to PCR tubes. The PCR mastermix is then evenly distributed over all PCR 
tubes. The primers amplify the gRNA cassette. The length of the amplicon corresponds to the number of gRNA 
cassettes present. D Analytical agarose gel of a 4xSTAgR cloning and colony PCR. E Statistics of the 
optimization process of STAgR cloning. The same set of building blocks was assembled in different ratios and 
the reaction was stopped at different timepoints. The timepoints were 20, 30, 40, and 60 min. The building 
blocks were combined in molar equality, 1:3, 1:5 and 3:1(vector to inserts) (n =48). F Quantification of cloning 
efficiencies from three different 4xSTAgR reactions using optimized conditions (molar equality and 40 min 
incubation time) (n =130). Parts of this figure were modified and taken from C. T. Breunig et al. 2018a. 
1.2 STAgR gRNAs are expressed individually and functionally 
Each gRNA within a STAgR vector is driven by its own promoter. Therefore, every single 
unit has to be expressed individually to form operational gRNA molecules. Unfortunately, 
quantification and verification of expression levels of individual gRNAs is still challenging by 
conventional methods. 
In order to ascertain that STAgR vectors functionally express multiple gRNAs, I conducted a 
genetic assay using WTCas9. In this experiment, a multiplexed STAgR vector was directly 
compared to a gRNA vector only carrying one gRNA. This gRNA targets the open reading 
frame of the gene coding for a destabilized version of the green fluorescence protein GFP 
(d2GFP) with a significant shorter protein half-life (Corish and Tyler-Smith 1999). If 
expressed, this gRNA in combination with WTCas9 can cause genetic alterations which often 
lead to loss of a functional GFP gene. By the loss of GFP signal, gRNA expression can be 
quantified directly. The GFP targeting gRNA was cloned into four different STAgR 
constructs with each four gRNA cassettes in total. In these constructs, the GFP targeting 
gRNA was incorporated on four different positions, followed or flanked by non-targeting 
control gRNAs. All STAgR plasmids as well as single gRNA plasmids were then individually 
transfected into HeLa cells stably expressing d2GFP and WTCas9. Eight days after 
transfection, cells were analyzed by flow cytometry. When only a single GFP targeting gRNA 
is provided to the system, 72% of cells lose GFP expression. This indicates a successful 
disruption of the open reading frame by induction of indel mutations. All four STAgR 
plasmids trigger similar GFP loss indicating that gRNAs at all four positions are expressed 
and functional.  
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Fig. 9│Functional validation of a 4-gRNA STAgR vector. A Five gRNA plasmids have been generated 
carrying a gRNA targeting the open reading frame of GFP. This gRNA is either in a single gRNA vector or four 
different STAgR constructs located on four different positions. These constructs were generated to make sure 
that all gRNAs are expressed to same levels. B Visualization of GFP negative cells obtained by mutation of the 
open reading frame of the fluorescence marker. The STAgR constructs and the single gRNA vector were 
transfected into a N2A cells stably expressing d2GFP, a fast degrading version of GFP. Every gRNA construct 
expressed the gRNA targeting GFP and therefore could guide WTCas9 to the genomic location of the 
fluorescence protein and induce indel mutations. This could be done to similar levels compared to the single 
gRNA construct, indicating that all gRNAs are expressed to similar levels. C Individual FACS blots of 
experiments shown in B. After transfection with WTCas9 and the gRNA plasmids cells clearly lost GFP 
expression due to the mutations induced by WTCas9. Parts of this figure were modified and taken from C. T. 
Breunig et al. 2018a. 
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1.3 STAgR is highly customizable 
As the CRISPR/Cas9 based transcriptional as well as epigenomic engineering field is steadily 
advancing, it is important for a universal multiplexing strategy to be easily adaptable to 
different means. A series of strings were generated featuring different Pol III promoters. 
Figure 10 shows the cloning of a STAgR construct with 4 different gRNAs, each driven by 
different promoters (human U6, mouse U6, human 7SK and H1). In addition to promoters, the 
gRNA scaffold can be substituted by different sequences as well. Two MS2-binding loops 
(henceforth called “SAM” loop) can be integrated into the scaffold sequence in order to 
utilize the gRNA with an MS2 binding protein-based system (Konermann et al. 2014a). 
Cloning of highly customized constructs with varying promoter and scaffold sequences 
showed a 30% efficiency of correct assembly, comparable to that of standard STAgR 
constructs (Fig. 10B). The versatility and simplicity of STAgR enables the combination of 
different Cas9 variants, MS2 fusion proteins, and dCas9 chromatin modifiers and indicates a 
decisive advantage over other multiplexing systems (Fig. 11A).  
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Fig. 10│STAgR is highly customizable. A This construct was engineered to harbor four different promoters as 
wells as SAM gRNA stem loops to be able to combine it with additional RNA- protein interaction based 
targeting systems. B Analytical agarose gel of the indicated STAgR construct carrying four different promoters 
as well as different gRNA stem loops. 1.5% agarose gel, stained with SYBR Safe. Parts of this figure were 
modified and taken from C. T. Breunig et al. 2018a/b.  
Gibson cloning is dependent on homologous sequences and STAgR cloning is based on 
repetitive building blocks. The limit for STAgR cloning is four gRNA cassettes when using 
the same promoter as well as the same gRNA scaffold. Using more than four gRNA cassettes 
with identical promoters and scaffold sequences never yielded the correct product, likely due 
to unwanted internal recombination events. However, it is possible to assemble up to 8 
expression cassettes into one vector in a single step reaction by changing the gRNA driving 
Pol III promoter as well as the gRNA scaffold (from the conventional scaffold to SAM) after 
the fourth gRNA (Fig. 11B). A colony PCR ladder with all possible numbers of gRNA units 
is depicted in Figure 11C.  
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Fig. 11│Visualization of the possibilities provided by STAgR cloning. A By combining different gRNA stem 
loops in one single gRNA plasmid one can target different loci with different effectors. B 8x STAgR could be 
created by changing to different promoters and different stem loops after 4 identical gRNA expression cassettes. 
C With STAgR, gRNA multiplexed vectors with 1 to 8 gRNAs can be created. This analytical gel shows a PCR 
of all obtained multiplexed cassettes. Parts of this figure were modified and taken from C. T. Breunig et al. 
2018a. 
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1.4 Use of STAgR for improved and combinatorial transcriptional activation 
Before potential multiplexing strategies, experiments relied on delivery of a cocktail of 
multiple gRNA plasmids, viruses, or molecules to cells. To test whether multiplexing gRNAs 
is beneficial for transcriptional engineering, a STAgR vector was produced carrying four 
different gRNAs. These gRNAs target the promoter regions of three different genes: the 
neuronal gene Satb2, the cardiac muscle actin gene Actc1, and Ttn1 (targeted by two gRNAs) 
(Fig. 12A). The STAgR plasmid carrying a tdTomato fluorescence marker was transfected 
into P19 cells alongside a construct expressing the transcriptional activator dCas9’VPR and a 
GFP fluorescence marker. As a control, the cells were transfected with dCas9’VPR and a mix 
of single gRNA plasmids containing the exact same gRNA protospacer sequences as the 
STAgR plasmid. After five days, GFP
+
/tdTomato
+
 positive cells were isolated by 
fluorescence activated cell sorting (FACS) and RNA was extracted. Relative amount of 
mRNA of targeted genes was analyzed using qPCR. qPCR of the targeted genes showed that 
using STAgR, two out of three genes could be activated to a higher level than by using only a 
cocktail of single gRNA plasmids (Fig. 12B). This indicates a distinct advantage of 
multiplexing gRNA vectors for multiple gene activation using transcriptional engineering.  
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Fig. 12│STAgR compared to single gRNA vectors. A Comparison of a 4x STAgR and a pool of single gRNA 
plasmids. Plasmid cocktails have been transfected into P19 cells alongside dCas9’VPR and mRNA levels were 
assayed by qPCR. B Two out of three target genes showed a higher increase of mRNA levels when the gRNAs 
were supplied by STAgR constructs, compared to a mix of single gRNA vectors. Error bars depict standard 
errors of the mean. 
1.5 Simultaneous disruption of multiple genes in vivo 
To test if Cas9 and STAgR could be used to efficiently and simultaneously disrupt multiple 
genes in individual cells in vivo, a STAgR vector was produced with gRNAs targeting the 
ORF of GFP and Sox2. The gRNAs were electroporated alongside a plasmid expressing 
WTCas9 into ependymoglia of three and a half months old GFAP-GFP transgenic zebrafish 
(Tg(gfap:GFP) (n=20) as previously described (Fig. 13A) (Barbosa et al. 2015, 2016) and 
shown in Durovic and Ninkovic, 2019. Seven days after electroporation, zebrafish brains were 
analyzed by immunofluorescence microscopy. In all animals analyzed, expression of GFP as 
well as of Sox2 is lost in a large number of ependymoglia, while control plasmids do not 
disrupt expression of either gene. It is striking that in most cells which lost the expression of 
one gene the other gene targeted is disrupted as well, certifying the efficient multiple gene 
targeting with multiplexed gRNA vectors using STAgR in vivo (Fig. 13B) 
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Fig. 13│In vivo use of STAgR. A A 4x STAgR construct with two gRNAs targeting the open reading frame of 
GFP as well as Sox2 were cloned and side by side with WTCas9 electroporated into GFAP:GFP transgenic 
zebrafish telencephali. B 3D reconstruction of whole mount Tg(gfap:GFP) zebrafish telencephali. WTCas9 
disrupted the open reading frames of GFP and Sox2 when guided by the STAgR constructs. A control plasmid 
did not evoke any loss of GFP or Sox2. Scalebar: 50µm.  
2. Development of novel de novo dCas9 methylation tools  
As introduced in section A3.2, options for targeted de novo methylation is currently far from 
perfect. Lacking specificity and displaying significant off- target effects, CRISPR/dCas9 
based de novo methylation requires the further development of new tools (Lin et al. 2018). 
During this thesis, new potential methylation tools were generated. To circumvent a possible 
interaction and control with and by host- factors, I designed and generated tools based on non- 
human or non- murine methyltransferases. I also aimed to generate tools to induce non- CpG 
methylation patterns. Four methyltransferases were picked for further testing. Based on 
functional description provided in the UniProt database (http://www.uniprot.org/) two 
methyltransferases, DRM2_ARATH (PaxDb number: Q9M548) and DNM1A_ORYSJ 
(PaxDb number: Q7Y117) were picked. DRM2_ARATH is a methyltransferase which 
originates from the mouse-ear cress, Arabidopsis thaliana. The Arabidopsis thaliana DNMT3 
cytosine methyltransferase ortholog DOMAINS rearranged methyltransferase2 (DMR2) is in 
control of the non- CpG methylation pattern CpNpG and it is also responsible for asymmetric 
methylation patterns. DRM2 was shown to be needed in RNA-directed de novo methylation 
of cytosines in all sequence contexts (Henderson et al. 2010; Naumann et al. 2011). DNA 
(cytosine-5)-methyltransferase 1A (DNM1A) encoded by the gene MET1A originates from 
the subspecies japonica of Oryza sativa (rice). It is known to methylate CpG residues and has 
a significant role in de novo DNA methylation (Teerawanichpan et al. 2004; Yamauchi et al. 
2014). It may also be involved in DNA methylation dependent gene silencing 
(Teerawanichpan et al. 2004) and play a minor role in DNA methylation maintenance 
(Yamauchi et al. 2014). The third methyltransferase, M.SSS1, is derived from the prokaryotic 
family of Spiroplasma monobiae, more specifically strain MQ1 (Renbaum et al. 1990). It is a 
de novo methyltransferase targeting exclusively CpG residues which are then completely 
methylated. The fourth and last methyltransferase-dCas9 fusion generated was based on a 
cytosine- 5- DNA methyltransferase derived from Chlorella virus NYs-1. The enzyme is 
called M.CVIPI and in contrast to most other mammalian methyltransferases, this enzyme 
recognizes the dinucleotide GpC. All constructs were generated as a fusion to dCas9 and 
codon optimized for mammalian expression (Fig. 14A).  
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To test the potential methylation capacity of the newly generated tools, a variety of 
transcriptional assays were performed. The first assay was based on the effect of methylation 
of the CAG promoter. This promoter has been reported to be sensitive to methylation. 
Methylation of the CAG promoter sequence results in downregulation of transcription of 
transgenes (Y. Zhou et al. 2014). Neuro2a cells which stably express a GFP fluorescence 
marker under the control of a CAG promoter were transfected with the DNA methylation 
fusion constructs DNMT3A and SSS1 alongside a three- times STAgR construct targeting 
three different sites of the CAG promoter sequence (Fig. 14B). Cells were analyzed by flow 
cytometry after five days. However, none of the constructs reduced the number of GFP -
expressing cells, not even dCas9’SSS1 or dCas9’DNMT3A which were already reported as 
DNA methylation tools by others (Lei et al. 2017b; X. S. Liu et al. 2016b; Vojta et al. 2016b).  
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Fig. 14│Potential new dCas9 de novo methylation tools A Scheme of newly produced dCas9 
methyltransferase tools. B Three gRNAs were designed to target a CAG promoter. This STAgR was then 
transfected alongside DNA methyltransferases into cells expressing d2GFP under the control of the CAG 
promoter. Percentage of GFP negative cells was measured by flow cytometry. C Four gRNAs were designed to 
guide dCas9 fusion constructs to the ICE CpG of lncRNA Airn. Transfected cells were isolated using flow 
cytometry and Airn levels were determined by qPCR. Depicted are the differences between the Ct thresholds of 
the AIRN transcript and a housekeeper GAPDH. As a control a 4x STAgR has been transfected, carrying non 
targeting gRNAs (“n.T.”). 
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To test the potential of engineered methyltransferases on a promoter known to be silenced by 
DNA methylation during development, I changed the experimental paradigm. Methylation of 
the CpG island at the 5’ end of the long non-coding RNA Airn is responsible for silencing of 
the maternal gene copy (Koerner et al. 2012; Latos et al. 2009; Stefan H Stricker et al. 2008). 
Any murine cell should therefore only show expression of the paternal gene which in theory is 
also sensitive to methylation of its CpG island. Therefore, I reasoned that targeted methylation 
of this CpG island should lead to a down-regulation of the Airn transcript. To test this, I 
designed four gRNAs that target different parts of the Airn CpG island and combined them in 
a tdTomato-expressing STAgR plasmid. The gRNAs were co- transfected together with one 
of the dCas9-methyltransferase fusion plasmids and double-positive (GFP
+
/tdTomato
+
) cells 
were isolated via FACS after 4 days. Airn levels were quantified by RT PCR. However, none 
of the tested methyltransferases was able to change the expression level of Airn relative to 
non-targeting controls (Fig. 14C). 
Monitoring Airn expression by qPCR did not yield any conclusive results. In order to monitor 
the consequences of target site methylation more easily, a methylation-sensitive fluorescence 
reporter was engineered. This reporter is based on a 3.7 kb region upstream of the annotated 
Airn transcription start site including the CpG island, which was defined to be the lncRNA’s 
promoter. Downstream of this promoter region a tdTomato sequence was inserted (Fig. 15A). 
When cells were transfected with this construct, they showed mild but detectable mCherry 
expression. A splice acceptor sequence and an IRES sequence were inserted between 
promoter and fluorescence gene to ensure the transcription of functional mCherry mRNA as 
well as the translation to a functional red fluorescence protein if Airn transcription should be 
initiated sooner than after the end of its CpG island (Pelletier and Sonenberg 1988). This 
construct was stably integrated into a human embryonic kidney 293T (HEK293T) cell using a 
PiggyBAC system in order to circumvent possible host regulation of the murine Airn 
promoter. Over a period of 24 days, transfected cells were FACS sorted six times to isolate 
the cells showing the strongest expression of the mCherry reporter sequence (Fig. 15A). Once 
this population was stably isolated, these cells were transfected with the Airn 4x STAgR 
construct (now carrying a BFP Reporter) and the dCas9-methyltransferase fusion constructs. 
GFP
+
/BFP
+
 double positive cells were analyzed and the number of mCherry-negative cells 
scored, compared to a control population. All tested constructs did not lead to a reduction of 
tdTomato fluorescence. Exemplarily shown in Figure 15B are the published and therefore as 
positive controls chosen DNA methyltransferases DNMT3A and DNMT3A3L. However, 
none of the targeted methyltransferases led to a change in fluorescence reporter expression.  
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Fig. 15│Generation of an AIRN Promoter fluorescence reporter. A A 3kb region including the CpG island 
of the Airn promoter was cloned in a PiggyBAC vector upstream of a splice acceptor and IRES and a dsRED 
fluorescence cassette. This vector was then transfected into HEK293T cells alongside a transposase plasmid. 
Cell which showed bright red fluorescence were enriched using FACS over several sorts to establish a brightly 
expressed fluorescence reporter driven by the Airn Promoter. B Airn reporter cells were transfected with gRNAs 
targeting the CpG island of the Airn Promoter and the dCas9-methyltransferase fusion constructs. Exemplarily 
shown are FACS blots of a dCas9 control, DNMT3A and DNMT3A3L.  
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By transcriptional read outs no changes could be observed. Next, I decided to test if targeted 
methylation even occurred, by analyzing the targeted sequences on a molecular level by 
bisulfite sequencing. For this, all methyltransferases as well as a non- methyltransferase 
control (dCas9’VPR) was targeted to different loci. Four gRNAs were assembled in one 
tdTomato- STAgR construct targeting the CpG island of Igf2r Non- Protein Coding RNA 
(Airn) as previously described. In addition, two gRNAs that target the promoter region of 
Ube2s were designed. This region is un- methylated in murine cells and was analyzed to 
monitor potential global methylation changes (off- target effects). P19 cells were transfected 
using lipofectamin with either the two- times STAgR targeting Ube2s or the four gRNA 
construct alongside each of the methyltransferases (DNMT3A, DNMT3A3L, DNM1A, 
DRM2, M.CVIPI) as well as dCas9’VPR as a control. All modifier plasmids carried a GFP 
expression cassette, driven by an independent CMV promoter. Two days after lipofection, 
positive cells for both fluorescent markers were isolated using FACS. DNA was isolated and 
bisulfite converted and prepared for subsequent bisulfite PCR and sequencing (Fig. 16). 
Surprisingly, none of the used methyltransferases resulted in higher methylation levels at 
targeted loci compared to base methylation levels of untreated cells or cells which obtained 
dCas9’VPR as a non- methyltransferase control. The strongest effects were observed from 
position 150 to 275 and showed approximately 1.5 fold higher methylation levels when 
targeted by DRM2, compared to VPR and P19. Some of the analysed cytosines (position 563 
to 688) even showed lower methylation levels when targeted with DNMT3A3L or M.CVIPI 
(Fig. 17). The outcome of targeting the locus of Ube2s was similar; the locus remained un- 
methylated with all tested constructs (Fig. 18).  
 
Fig. 16│Scheme of the experimental paradigm of bisulfite sequencing of the Airn CpG island. 
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Fig. 17│Bisulfite sequencing of the AIRN CpG island and Ube2s promoter after targeting the AIRN CpG 
P19 cells were transfected using lipofectamin. They received a mix of dCas9’Effector and a 4x STAgR construct 
with gRNAs targeting the AIRn promoter. Each dot represents one CpG analysed by sequencing. The darker the 
dot the more methylation signal. The methyltransferases DNM1A, DNMT3A, DNMT3A3L, DRM2 and 
M.CVIPI were targeted to the CpG island of the Airn locus. dCas9’VPR was used as a negative control. The 
promoter region of Ube2s was analysed to control for potential unspecific treatment effects. “P19” resembles the 
baseline. Here non- transfected cells were analyzed.  
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Fig. 18│ Bisulfite sequencing of the AIRN CpG island and Ube2s promoter after targeting the Ube2s 
promoter P19 cells were transfected using lipofectamin. They received a mix of dCas9’Effector and a 2x 
STAgR construct with gRNAs targeting the Ube2s promoter. Each dot represents one CpG analysed by 
sequencing. The darker the dot the more methylation signal. The methyltransferases DNM1A, DNMT3A, 
DNMT3A3L, DRM2 and M.CVIPI were targeted to the promoter region of the gene Ube2s. As a non- active 
control dCas9’VPR was used. 
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3. Manipulation of DNA methylation marks associated with Alzheimer ’s disease 
Developing tools to be able to manipulate disease associated methylation marks was an 
overall goal of this PhD project. This should be done to be able to directly link methylation to 
disease development or progression. The chromatin marks which were planned to be 
manipulated were reported to be hypermethylated in Alzheimer’s disease. These differentially 
methylated positions (DMPs) were, amongst others, in close proximity to the Alzheimer’s 
Disease associated genes ANK1 and RHBDF2 (cg05066959, cg11823178, cg05810363, 
cg23968456, cg03169557) (Fig. 5/19) (De Jager et al. 2014; Lunnon et al. 2014).  
 
Fig. 19│Scheme of the different methylated positions found in two independent EWA studies. 
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The absolute methylation levels of analyzed samples during the conducted EWAS are not 
apparent from the published data and an access to raw data was not given. Hence, I first set 
out to determine the baseline methylation status at the loci of interest in the model systems, in 
which I planned to manipulate them. These were human embryonic neural stem cell lines 
CB130, CB152 and CB660 and human induced pluripotent stem cells (iPSCs) as well as 
neurons derived from these cells (Fig. 20A). To gain insight into the methylation status of the 
loci in an AD-dependent manner, two engineered iPSC lines were analyzed as well. These 
lines carry heterozygous and homozygous mutations in the amyloid precursor protein (APP) 
and presenilin 1 (PSEN1) associated with early-onset Alzheimer’s disease (Paquet et al. 
2016). Hereafter, cells harboring these mutations are referred to as “P4C4” and “P2B5”. They 
were compared to a non- engineered line (7889SA, hereafter “WT”). DNA was isolated and 
bisulfite converted. The loci were amplified, libraries prepared and analyzed by next 
generation sequencing (NGS) (Fig. 20B/C).  
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Fig. 20│Bisulfite sequencing of the 5 DMPs. A Brightfield images of the three human neural stem cell lines on 
which this study should have been based, CB660, CB130, and CB152. B Analytical agarose gel depicting the 
different loci after bisulfite treatment and site specific PCR. C Representative image of a bisulfite sequencing 
library, analyzed via BioAnalyzer.  
Surprisingly iPSCs of all three genetic backgrounds already carry high methylation levels at 
all the positions analyzed. Nearly all of the sites whose hypermethylation has been associated 
to Alzheimer’s disease progression show methylation rates higher than 90%. Only DMP1 
showed methylation rates lower than 90% (83% in WT iPSCs, 79% in P2B5 iPSCs). The 
different disease associated mutations did not yield any significant differences in methylation 
levels (Fig. 21A). Next, I tested three different human foetal neural stem cell lines. These 
stem cell lines conveniently ensure a renewable and scaleable supply of tripotent (astrocytes, 
oligodendrocytes and neurons) cells which provide a valuable resource for applied 
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neurobiology (Sun et al. 2008). In total, three different neural progenitor cell lines (CB130, 
CB152, CB660) were planned to be used and were therefore analyzed on their current 
methylation status of DMP1 to DMP5. Three out of five DMPs in all neural progenitor lines 
displayed high methylation states. The methylation levels ranked from 95% (DMP3 CB152) 
to 99% (DMP2 CP152, DMP4 CB660). Merely DMP1 and DMP5 showed a different picture. 
At CpG cg05066959 (DMP1) bisulfite sequencing revealed that only around 50 to 60% of 
analyzed cells of cell lines CB130 and CB660 are fully methylated. Furthermore in the cell 
line CB152, DMP1 is methylated to 83%. With DMP5 the inconsistency continues; 
methylation levels varied here from around 50% (CB130 and CB152) to 92% (CB660) (Fig. 
21C). This clearly indicates the high variability of methylation rates of the analyzed loci 
dependent on the genetic background.  
 
Fig. 21│Bisulfite sequencing data of different cellular cultures. The analyzed loci DMP1 - 5 refer to 
cg05066959,cg11823178, cg05810363, cg23968456, cg03169557. A Methylation status of different iPSC lines. 
Strains which were analysed were WT iPSC and two iPSC lines carrying familiar Alzheimer’s disease 
mutations. B Methylation status of different neuronal lines. The following strains were analysed: WT neurons 
and two neuron lines carrying familiar Alzheimer’s disease mutations. C Methylation status of the three neural 
stem cell lines shown in Fig20A. D Methylation status of  astrocytes generated in vitro as well as a non- 
cultured, control cells isolated from the buffy coat of human blood.  
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To test the disease-affected cellular type, neurons derived from previously described iPSCs 
were analyzed next. Here, all DMPs analysed showed methylation levels higher than 90% and 
the different disease mutations did not cause any differences in methylation levels (Fig. 21B). 
Even though neurons are the affected cell type, other cellular subclasses could be responsible 
for disease development as well. The EWA studies analyzed methylation rates not as cell type 
specific as conducted during this thesis. This is why the spectrum of evaluated cell types was 
extended. From human iPSC derived astrocytes were analyzed for their current methylation 
status at the different methylated positions. Overall, DMP1 to DMP4 showed elevated 
methylation levels. Here a striking 99.9% of all analyzed cells harbored fully methylated 
CpGs at all positions. In astrocytes DMP5 shows reduced methylation levels. This CpG 
dinucleotide is fully methylated in only 54.5% of the analyzed cellular population (Fig. 21D). 
Again, individual DMPs were not as highly methylated as in other samples, further indicating 
large variation between different cellular types. Nonetheless, this shows clearly that not only 
iPSCs, neurons or the different neural stem cells show high methylation rates at the analyzed 
loci, but astrocytes as well.  
Reportedly, in vitro culturing can have severe influence on the global methylation level and 
can induce aberrant hypermethylation in specific regions over extended proliferation 
(Meissner et al. 2008). It is additionally debatable if methylation patterns in vitro resemble 
methylation levels in corresponding in vivo celltypes (de Boni et al. 2018). To exclude that 
this holds true for the analyzed positions and the encountered hypermethylation is an artefact 
of in vitro culturing and differentiation, cells from the buffy coat of human blood was 
analyzed. In these in vivo control cells, methylation levels ranged from 80% (DMP5) to 
99.8% (DMP4) and overall showed a comparable picture to all other analyzed in vitro 
samples (Fig. 21D). As it still remains unclear whether epigenetic patterns found in in vitro 
differentiated neurons resemble those detectable in native brains neurons, human brain cortex 
tissue was analysed in the same way as previously described (de Boni et al. 2018). Here white 
matter tissue was separated from grey matter tissue and analysed individually. Grey matter 
samples showed methylation levels of 96.6% (DMP1), 77.9% (DMP2), 91.9% (DMP3), 
88.9% (DMP4) and 79.8% at DMP5 (Fig. 22A). The white matter sample displayed slightly 
reduced methylation levels with 97% at DMP1, only 65.7% at DMP2, 83.5% at DMP3, 
84.6% at DMP4 and 79.6% at DMP5. Overall the methylation did not differ dramatically 
from previously analysed tissue (Fig. 22B). 
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Fig. 22│Bisulfite Sequencing data of human brain samples. A Methylation status of the 5 DMPs in post 
mortem human grey matter from cortex samples. B Methylation status of the 5 DMPs in post mortem human 
white matter from cortex samples. 
During Bisulfite sequencing and after conversion, the different loci are amplified with strand 
specific primers. This means that during the classical version of this procedure one actively 
selects for one strand or the other (Darst et al. 2010). DNA methylation is generally a 
symmetric chromatin modification which means that the cytosines of a CpG dinucleotide are 
modified on both strands (L. Zhao et al. 2014). Nonetheless, this pattern is temporarily 
disrupted during DNA replication, when the newly synthesized and unmethylated daughter- 
strand forms a asymmetrically methylated CpG dyad called hemimethylated DNA (Sharif and 
Koseki 2018). This state was thought to not exist permanently, as either the still methylated 
strand was thought to be demethylated or vice versa, the non- methylated strand to be 
modified. But apparently this did not hold true, as about 10% of all CpGs in embryonic stem 
cells seem to be hemi-methylated permanently (L. Zhao et al. 2014). To confirm previously 
obtained data and to rule out possible hemi-methylation, the bottom strand of the five DMPs 
was analysed as well.  
Figure 23 shows the differences of methylation levels in percent of top and bottom strand. 
Here, four different examples are shown as representatives for the different analyzed cell- and 
tissue types. In P4C4 iPSCs, P2B5 neurons, human blood buffy coat and human white matter, 
none of the differences between the two strands are higher than 15%. Both analyzed strands 
show some variation, but nonetheless both sides of each CpG are equally hypermethylated, 
confirming the previously obtained datasets (Fig. 24).  
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Fig. 23│Bisulfite sequencing data of the antisense sequences of the five DMPs from previously analysed 
samples. Exemplarily for all samples P4C4 iPSCs, P2B5 neurons, blood and white matter are shown.  
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Fig. 24│Visual summary of bisulfite sequencing data of sense loci. The darker the squares the higher 
methylated are the different positions. Numbers indicate the CpG dinucleotides in the analysed sequences. The 
red line marks the CpG islands which were previously found to be methylated in Alzheimer’s disease. The locus 
of Ube2b was analysed to exclude errors during bisulfite conversion. 
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4. Transcriptional engineering of layer specific subtype defining transcription 
factors to achieve neuronal reprogramming 
Transcriptional engineering, the manipulation of endogenous gene copies with dCas9 
activators holds a tremendous potential for certain questions in biology. Reprogrammed 
neurons often display a lack of maturity. This means that cells can be transformed into this 
desired cell type, the newly generated neurons though show for example expression of deep 
layer markers, even if located in the upper layers of the brain (Gascón et al. 2016). I reasoned 
that targeting and activation of multiple factors at once, even if individual factors only play a 
minor role, could help to orchestrate cells during the transformation process to a subtype 
specific state. With the establishment of the STAgR technique, I developed a solid basis for 
extending the transcriptional engineering tools towards these applications. 
4.1 Candidates for callosal projection neurons  
All gRNAs were chosen making use of the UCSC genome browser track “CRISPR10K”. This 
track combines various algorithms to assign a quality score for every single gRNA. The score 
predicts potential off target effects and binding efficiency (Bae et al. 2014; Doench et al. 
2014; Doench et al. 2016; Haeussler et al. 2016; Moreno-Mateos et al. 2015). Since published 
data indicates that two gRNAs targeting a promoter region are improving for solid gene 
activation (Chavez et al. 2015; Cheng et al. 2013; Maeder et al. 2013), I designed two gRNAs 
for each gene. Since it has been reported that gRNAs should bind in close proximity to the 
gene’s transcriptional start site, one in the first 100bp upstream and the second within 300bp 
(but at least 100bp apart from each other) (Wang, La Russa, and Qi 2016), I followed these 
principles of gRNA design (Fig. 25).  
 
Fig. 25│Scheme of transcriptional engineering setup. To successfully induce the transcription of a target gene 
with dCas9 based tools one needs to target a locus with two different gRNAs. These gRNAs should target within 
300bp and should be located at least 100bp apart from each other.  
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The candidates, which have been chosen as potential callosal projection neuron 
reprogramming factors were Satb2, Cux2, Cux1, Mef2c, Tle2, Lhx2, Bhlhb5, Brn2 and Nurr1. 
It has been tested if dCas9 based transactivators can upregulate mRNA levels when targeted 
in different cell lines (Fig. 26- 30). Firstly, two different genes have been in the focus, Satb2 
and Cux2. Satb2 is located on murine chromosome 1 and has three annotated isoforms with 
different transcriptional starting sites which are all around 500 bp apart (Fig. 26A). For Satb2, 
two sets of two gRNAs each were designed, targeting different isoforms. The gRNAs S1 and 
S2 targeted the isoform starting at Chr1:56,793,986 (Gencode Transcript: 
ENSMUST00000114415.9), whereas gRNAs S3 and S4 targeted the variant with gencode 
transcript: ENSMUST00000042857.13. For both sets, single gRNA plasmids carrying a 
tdTomato fluorescence reporter were generated and transfected alongside a plasmid carrying a 
dCas9’VP64 fusion protein and a fluorescence reporter into P19 cells. After five days, double 
positive cells were isolated via FACS, whole RNA was isolated and Satb2 levels analyzed by 
qPCR. Compared to a non-targeting control, in combination with dCas9`VP64, gRNA S1 and 
gRNA S2 could raise the mRNA level of Satb2 6-fold. When guided by gRNA S3 and S4, 
mRNA levels were increased around 9.2 times, indicating that the latter gRNAs are more 
potent. A combination of all four gRNAs did not raise the mRNA levels of Satb2 any further. 
The second gene targeted was Cux2 (Cut- like homebox 2). I tested sets for two different 
transcriptional start sites of Cux2 containing three gRNAs each. The gRNAs C2.1, C2.2 and 
C2.3 targeted the annotated starting site of transcript variant 2 (Gencode Transcript: 
ENSMUST00000111752.9) whereas gRNAs C2.4, C2.5 and C2.6 targeted transcript variant 1 
(Gencode Transcript: ENSMUST00000086317.11) (Fig. 26B). When applied alongside 
dCas9’VP64, neither gRNA set 1 nor gRNA set 2 were able to increase mRNA levels of Cux2 
to more than 2.5 fold.  
As the CRISPR field is rapidly evolving, novel tools are generated constantly. Building on 
dCas9’VP64, Chavez et al. created a hybrid fusion protein existing of classical VP64, p65, a 
subunit of transcription factor NF- κB and Rta, a transcription factor of Epstein- Barr virus 
(Chavez et al. 2015). This novel transcriptional activator termed VPR was shown to be 
significantly more potent when fused to dCas9 and targeted to an engineered fluorescence 
reporter (Chavez et al. 2015). To test this advanced tool, P19 cells were transfected with a 
construct providing an overexpression of dCas9’VPR alongside the gRNAs which were found 
to be most potent with dCas9’VP64 in activating transcription of Satb2 and Cux2. This time 
gRNAs were also applied individually to test for the minimum requirements to induce mRNA 
levels of both factors significantly. As seen in Figure 27, the application of VPR enhanced the 
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induction of Satb2 mRNA levels in comparison to VP64 roughly 5- fold, to an overall fold 
increase of 50- times over a non- targeting control. This confirmed VPR to be a more potent 
transcriptional activator. Furthermore, it was apparent that the combination of gRNAs S3 and 
S4 showed a synergistic effect, as single applications did not add up to the same mRNA levels 
of Satb2. For Cux2 however, single gRNAs as well as the set of gRNA C2.1 to C2.3 did not 
increase the mRNA levels to more than 2- fold, showing no further improvement by the use of 
dCas9’VPR. As there is one additional transcriptional starting site annotated for Cux2, 
another set of three gRNAs was designed and tested (Gencode Transcript: 
ENSMUST00000168288.8). However, these gRNAs did not activate Cux2 transcription 
either (data not shown) suggesting that other limitations or barriers to transcriptional 
engineering could interfere with a successful induction, as we have experienced before 
(Baumann et al. 2019).  
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Fig. 26│Schemes of gRNA binding at Satb2 and Cux2 loci as well as induction by dCas9’VP64. A Four 
gRNAs have been designed for two different annotated transcriptional starting sites for Satb2. P19 cells were 
transfected with transcriptional activator dCas9’VP64 and the different sets of gRNAs. The graph depicts the 
mRNA levels of Satb2 analysed via qPCR. B Six gRNAs have been designed for two different annotated 
transcriptional starting sites for Cux2. P19 cells were transfected with transcriptional activator dCas9’VP64 and 
the different sets of gRNAs. The graph depicts the mRNA levels of Cux2 analysed via qPCR. 
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Fig. 27│Comparison of dCas9’VP64 and dCas9’VPR. The different gRNAs were supplied to two different 
transcriptional activators. A P19 cells were transfected with dCas9’VP64 or dCas9’VPR and the different gRNA 
combinations. mRNA levels were analysed by qPCR. B Comparison between VP64 and VPR by targeting the 
Cux2 locus with three different gRNAs.  
To test targeted gene activation for a larger set of subtype specific transcription factors I 
designed a pair of gRNAs for Mef2c, Cux1, Tle2, Lhx2, Bhlhb5, Brn2, and Nurr1 targeting an 
annotated transcriptional start site (Fig. 28A). Similar to Satb2, Bhlhb5 (Gencode Transcript: 
ENSMUST00000026120.7), Lhx2 (Gencode Transcript: ENSMUST00000143783.8), Brn2 
(Gencode Transcript: ENSMUST00000178174.2) and Nurr1 (Gencode Transcript: 
ENSMUST00000028166.8) mRNA levels could be elevated when targeted with dCas9’VPR 
in P19 cells (Fig. 29/30A). However, as seen for Cux2, transcription of Cux1 (Gencode 
Transcript: ENSMUST00000004097.15), Tle2 (Gencode Transcript: 
ENSMUST00000146358.7) and Mef2c (Gencode Transcript: ENSMUST00000005722.13) 
were only minorly or not induced by CRISPR transactivators (Fig. 29A).  
To test whether the transcriptional activation is dependent on the cellular system, I targeted 
these factors in two additional cellular models, postnatally isolated ex vivo astrocyte cultures 
and isolated mouse embryonic fibroblasts (MEF) (Fig. 28B). Similar as in P19 cells, 
transcriptional levels of Bhlhb5, Tle2 and Satb2 were increased in astrocytes and fibroblasts, 
although to slightly varying degree (Fig. 29B/C). Transcriptional induction of Lhx2, Brn2, 
Nurr1 and Cux1 varied in the different cellular models used (Fig. 29A/B/C). However, 
mRNA levels of Mef2c as well as Cux2 were not increased by dCas9’VPR in astrocytes nor in 
fibroblasts (Fig. 29B/C).  
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Fig. 28│Overview of factors chosen as candidates for callosal projection neuron reprogramming. A All 
derived factors were shown to influence the development of the upper cortex layers. Black bars indicate the 
positions relative to the transcription start sites of the genes. B Scheme of the different in vitro models which 
were used and experimental paradigm of transcriptional activation.  
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Fig. 29│Transcriptional manipulation of potential callosal projection neuronal reprogramming factors. A 
Activation of Mef2C, Cux1, Cux2, Tle2, Lhx2, Bhlhb5, Satb2 and Brn2 in P19 cells using sets of two different 
gRNAs each. B Activation of Mef2C, Cux1, Cux2, Tle2, Lhx2, Bhlhb5, Satb2 and Brn2 in primary astrocyte 
cultures using sets of two different gRNAs each. C Activation of Mef2C, Cux1, Cux2, Tle2, Lhx2, Bhlhb5, Satb2, 
and Brn2 in fibroblasts using sets of two different gRNAs each. 
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Since, Mef2c and Cux2 could not be activated significantly and Lhx2, Cux1, and Brn2 did not 
respond to transactivation in astrocytes, I tested whether this unresponsiveness is caused by 
targeting the wrong annotated transcription start site or wrong gRNA position. For this, 
alternative gRNA sets were designed, generated, and applied. Targeting with alternative 
gRNAs or targeting different transcription start sites improved mRNA induction for some of 
the factors, other levels could not be raised this way (Fig. 30A/B/C). For Brn2, three more 
gRNAs were tested in different combinations. With gRNA set B3/B5, Brn2 transcription 
could be raised higher than with previous sets in astrocytes (Fig. 30B). For Lhx2 
(“ENSMUST00000000253.5”) and Mef2c (“ENSMUST00000197146.4” and 
“ENSMUST00000185052.5”), two alternative gRNA sets were applied. Out of two gRNA 
pairs each, one increased mRNA levels, compared to previously targeted transcripts (Fig. 
30B). For Cux1 (“ENSMUST00000176216.8“) no gRNA set was found which raised levels 
over basal expression in astrocytes (Fig. 30A). To test whether transcriptional activation with 
these alternative gRNAs is variable in different cellular systems, they were applied in P19s 
and in fibroblasts. Consistent with previous data, mRNA induction in both cellular systems 
was overall higher, but transcription of similar factors was induced (Fig. 30A/C).  
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Fig. 30│Transcriptional manipulation with alternative gRNA sets of potential callosal projection neuronal 
reprogramming factors. Targeting with alternative gRNA sets of the factors which did not show a distinct 
activation in the first round. A in P19 cells B in astrocytes and C in fibroblasts. 
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4.2 Generation of an 8x STAgR and simultaneous activation 
Since in the previous experiments, Satb2, Bhlhb5, Lhx2, and Tle2 have been successfully 
induced by Cas9- based transactivation in astrocytes, I combined the most potent gRNA pairs 
onto two 4x STAgR plasmids. The gRNAs targeting the Satb2 promoter region (gRNAs S3 
and S4) were combined with the set for Bhlhb5, as well as Lhx2 targeting gRNAs L3 and L5 
with the pair for Tle2 (T2 and T3). All of these gRNAs were generated featuring the SAM 
gRNA scaffold to be compatible with all available dCas9 as well as MS2 based transcriptional 
activators. These 4xSTAgR expression cassettes were combined to an 8x gRNA expression 
vector (Fig. 31). To test whether simultaneous delivery and expression of eight gRNAs 
expression cassettes affect transcription activation, these constructs were tested alongside a 
plasmid coding for dCas9’VPR featuring a tdTomato reporter in primary astrocytes and 
fibroblasts. However, the qPCR analysis shown in Figure 31 indicates that the simultaneous 
activation had little adverse effect on the transcriptional level of the individual factors in 
astrocytes. All factors can be induced to comparable levels as when the gRNAs are supplied 
individually. In fibroblasts, transcription of all factors was induced but for two out of four 
factors, namely Satb2 and Bhlhb5, this induction was overall lower compared to the 
individual gene targeting. This overall indicated that multiplexed gRNA plasmids can be used 
to induce expression of multiple transcription factors simultaneously.  
 
Fig. 31│Generation of 8xSTAgR with potential callosal projection neuron reprogramming factor targeting 
gRNAs. dCas9’VPR was supplied with 8xSTAgR in Astrocytes and Fibroblasts and mRNA levels have been 
depicted via qPCR.  
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4.3 Development of a gRNA dependent reporter system 
To create a system, which provides the possibility to identify cells, which received both, 
gRNAs as well as dCas9 transactivators, I generated a reporter construct, regulated by the 
CRISPR transactivator itself. It is based on a minimal CMV promoter, which on its own is not 
strong enough to drive the fluorescence reporter, but does so, if it is targeted with the 
transactivator. To implement this strategy I included upstream of this promoter the targeting 
sequence of a used gRNA (e.g. Satb2 targeting gRNA S3). When this gRNA is expressed, it 
binds not only to the endogenous Satb2 promoter but will also bind the promoter region of the 
fluorophore reporter, subsequently inducing its transcription (Fig. 32A). I tested this 
functional activator reporter (FAR) system in P19 cells as well as in astrocytes. A plasmid 
coding for dCas9’VPR and a tdTomato fluorescence protein was transfected alongside the 
GFP functional activation reporter plasmid to monitor for activator expression. If no gRNA is 
supplied, GFP expression is not detectable by flow cytometry or microscopy (Fig. 32B/C). 
This changes if gRNA S3 is provided to guide dCas9’VPR to the promoter region of the 
reporter plasmids. When analyzed by flow cytometry, 35% of all cells show bright 
fluorescence (Fig. 32B). This induction was also detectable by fluorescence microscopy (Fig. 
32C). Utilization of this system does not only directly show which cell obtained the full 
system (even if subdivided into different vectors or viral particles), it also frees fluorescence 
channels for potential marker analysis by immunohistochemistry.  
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Fig. 32│Establishment of a Functional Activator Reporter. A Concept of the established Functional 
Activator Reporter. A gRNA will not only bind the endogenous promoter of a gene of interest but also the 
minimal CMV promoter region upstream of a fluorescence gene. Transcriptional activators will then induce its 
expression, highlighting the cells which got all parts of the system simultaneously. B Cells that only obtained the 
transcriptional activator and the reporter did not show any green fluorescence when analysed by flow cytometry 
(upper square). When dCas9’VPR was supplied with a gRNA targeting the reporter, 35% of all cells showed 
green fluorescence out of which 100% were dCas9 positive. C Imaging of a living astrocyte culture which 
obtained either no gRNA but dCas9’VPR (TdTomato) and the reporter plasmid (GFP) or the whole system and a 
targeting gRNA.  
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4.4 Adaption of the functional activator reporter to lentiviral delivery  
To test whether the designed and established experimental strategy based on the FAR reporter 
is suitable for viral delivery, I chose an alternative dCas9 activator toolset. As conventional 
dCas9’VPR fusion constructs exceed the packaging limit of a lentiviral particle, I chose a 
toolset which is based on the interaction of a repeating peptide array with an antibody- fusion 
protein, termed dCas9’SunTag (Fig. 33A) (Tanenbaum et al. 2014). This made it possible to 
separate the artificial transcription factor fusion GCN’p65’HSF1 with its shuttle and anchor 
dCas9’SunTag to be able to stay well under the maximum packaging limit of a lentivirus 
particle. The GCN antibody coupled artificial transcription factors were combined with the 
8xSTAgR construct like depicted in Figure 33B. Surprisingly when the 8x STAgR construct 
was packed with the additional GCN cassette, the FAR was expressed even without the trans-
activator itself, losing its actual purpose (Fig. 33C). Without the GCN cassette however, the 
8xSTAgR construct carrying the functional activity reporter only showed GFP expression 
when combined with a dCas9’VPR over expression. To test whether this leakiness can be 
prevented, the position of the GFP functional activator reporter’s expression cassette was 
changed to generate different cassette orders (Fig. 33B). However changing the GFP 
functional activator reporter’s position or orientation on the plasmid did not improve its 
leakiness. This indicates that combining the FAR with dCas9’SunTag based transactivators 
introduces unreliability.  
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Fig. 33│Transfer of the functional activator reporter into a lentiviral system for potential in vivo usage. A 
Overview of the dCas9SunTag system. B Schematic overview of the different constructs generated. C Flow 
cytometry blots showing GFP expression in dependence on which viral particles were provided.  
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In order to test if the FAR system is compatible with a different transactivator system, it was 
tested in primary mouse embryonic fibroblasts derived from the dCas9Activator mouse line 
(dCAM) (Fig. 34A) (Giehrl- Schwab et al. unpublished). The activator system in this 
transgenic mouse is based on dCas9’VPR which is supported by MS2 based artificial 
transcription factors which help to accumulate a high amount of activators at a target site 
(Konermann et al. 2014a). The transgene is under the control of a CAG promoter which is 
suppressed by a transcription Stop cassette, flanked by loxP sites and therefore removable 
using Cre recombinase (Hermann et al. 2014). Mouse Embryonic Fibroblasts (MEFs) were 
extracted from the dCAM mouse line and the loxP-STOP-loxP site was subsequently 
removed in vitro by transfecting a plasmid coding for Cre recombinase and a tdTomato 
fluorescence protein. The transfected cells (tdTomato
+
) were isolated by FACS and expanded. 
Viral particles were generated which featured a functional activator GFP reporter with a 
binding site for Satb2 targeting gRNA S3 and the corresponding single gRNA expression 
cassette. Cells were then transduced with this virus and analyzed by immunohistochemistry. 
When transduced with the single gRNA control particle, cells show widespread GFP 
expression. However when infected with the particle, containing an 8x STAgR construct also 
carrying a GFP reporter with an S3 gRNA binding site, only few cells showed GFP 
expression (Fig. 34B), indicating that the FAR is sensitive to the number of gRNAs used, 
especially in viral settings. 
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Fig. 34│Viral particles used in dCas9’Activator mouse-derived fibroblasts. A Schematic overview of the 
dCas9’Activator transgene engineered in the mouse line and the different lentiviruses used. B 
Immunohistochemistry of cultures infected with the functional activator reporter and either a control gRNA virus 
or the 8xSTAgR virus.  
To test whether the low count of GFP positive cells is due to the repetitive character of the 
8xSTAgR construct leading to low titer, I generated a construct, which carried the 8x STAgR 
gRNA expression cassettes but also coded for a constitutively expressed GFP under a CMV 
promoter. In two other constructs, the gRNA targeting the functional activator reporter was 
decoupled with its target to form two smaller lentiviral constructs (Fig. 35A). The lentiviral 
construct featuring the constitutively expressed GFP as well as the combination of both 
smaller viruses was applied in vitro. Whereas the culture transduced with the virus featuring 
the constitutively expressed GFP showed bright green fluorescence, the decoupled functional 
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activator reporter did not result in GFP expression (Fig. 35B). This suggests that the 
functional activator reporter is incompatible with lentiviral delivery and I therefore abandoned 
it for in vivo experiments focusing on constitutively expressed reporters. 
 
Fig. 35│Viral particle optimization for in vivo usage. A Schematic overview of the viral particles used. B 
Immunohistochemistry of P19 cultures infected with the constitutively expressed GFP 8xSTAgR and the 
decoupled functional activator reporter. After transduction, cells were transfected with dCas9’VPR’TdTomato  
4.5 In vivo injection after traumatic brain injury 
To be able to apply this system in vivo, I made use of the dCAM, crossed with a line that 
carries the Cre recombinase under the control of the Aldh1L1 promoter (Tien et al. 2012) 
(Fig. 36C). Offspring was genotyped using primers and protocols depicted in Tables 10/11. 
dCAM
+
/Cre
+
 double positive individuals were grown until three months of age. Mice were 
treated as described in chapter D5.3 to mimic a traumatic brain injury and injected with viral 
particles after three days (Fig. 36A/B). The mice were perfused and the brains were isolated 
and post-fixed for 24 hours. Brain slices of 50µm were prepared and analyzed by 
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immunohistochemistry (Fig. 36B). Figure 36B shows the cortex of a three months old mouse. 
GFAP staining (white) indicates the area of the stabwound as astroglia start to proliferate in 
the grey matter after acute injury (Simon, Götz, and Dimou 2011). After viral injection, cells 
with astrocyte morphology were identified which showed strong GFP expression and 
therefore obtained the 8xSTAgR gRNA construct. However whether the gRNAs in 
combination with the proneural factors NEUROD1 and NEUROD4 lead to layer specific 
reprogramming still needs to be elucidated and could not be accomplished until the end of this 
thesis. 
 
Fig. 36│Selective targeting of astrocytes with dCas9’VPR and STAgR at a site of brain injury in vivo. A 
Schematic overview of injury paradigm. B Immunohistochemistry of a 70µm brain slice at the injury site. GFAP 
staining indicates the location of injury. C dCas9 staining at an injury site of a dCas9 activator mouse crossed 
with an Ald1h1-Cre mouse line. Selective dCas9 expression can be seen in reactive astrocytes accumulating 
around the injury site. D Staining of GFAP (white) and GFP (green) after stabwound and injection of a 
8xSTAgR lentiviral particle, carrying a constitutive expressed GFP. 
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C. Discussion 
1. STAgR cloning based gRNA Multiplexing  
Experimental paradigms using Cas9/dCas9 to target multiple genes or loci need to avoid 
critical bottlenecks. In any approach that aims to target multiple genes or loci, the 
implementation of a reliable multiplexing strategy is essential to ensure each cell receives all 
the desired gRNA sequences. Co-transfection of large numbers of gRNA expression vectors 
will result in only a small fraction of cells receiving all essential targeting information in form 
of gRNAs in stoichiometric levels. It is possible to clone each gRNA into a different vector 
with a unique selection marker. However, the number of selectable constructs (antibiotic as 
well as fluorescent markers) is limited. An alternative approach is to clone multiple gRNA 
expression cassettes into a single-vector. Sequential insertion of these cassettes is 
cumbersome and time-consuming. Furthermore, CRISPR/Cas9-based approaches often 
necessitate a comprehensive validation of gRNA sequences. This implies that a flexible and 
customizable multiplexing strategy is advantageous. By using the N20 protospacer sequence 
as homology region for Gibson assembly, STAgR cloning provides said requirements in a 
fast, cheap, and highly efficient way. At the time of publication of the manuscript, STAgR 
enabled the cloning of an unprecedented number of gRNA cassettes in a single reaction. It is a 
simple method that does not rely on expensive or restricted materials and is easy to learn. The 
method enables comprehensive highly customizable gRNA multiplexing and makes it 
available to a large scientific community. STAgR cloning allows the utilization of most 
common gRNA vectors, thereby enabling a large set of experimental paradigms. Furthermore, 
its flexibility makes it compatible with various CRISPR-based approaches. A recent study has 
shown that combining different Cas9 tools can help to unravel the effect of epigenetic barriers 
on transcriptional reprogramming (Baumann et al. 2019). This only hints the potential of 
combining a conventional dCas9 targeted modifier or transcriptional activator with other 
protein- RNA interaction based targeting systems like the MS2 system (Konermann et al. 
2014a). With STAgR, a combination of different modified gRNA stem loops is fairly easy. 
Loci can be targeted with transcriptional activators with dCas9 based tools and others 
additionally with chromatin modifiers to remove epigenetic barriers by MS2 based targeting, 
while gRNAs are provided from one vector. With this, STAgR provides a possibility to 
further push and combine epigenetic and transcriptional engineering tools. More conventional 
WTCas9 based genetic engineering approaches could also heavily profit from this 
multiplexing strategy.  
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I showed that multiplexed gRNA vectors with the STAgR strategy can be reliably generated 
with high efficiency. However, the efficiency of the enzymatic assembly is dependent on the 
molar ratio the individual building blocks are represented and the reaction duration. I also 
encountered that efficiencies are dependent on the sequences of the generated N20 overhangs. 
Given that the enzymatic reaction, on which STAgR is based, is highly dependent on 
homologous sequences, certain motifs have to be avoided as N20 sequences. I found that 
polyT stretches and especially sequences which resemble the first 15bp of the used promoter 
can lead to premature termination of the STAgR reaction. Furthermore, the order of the 
individual N20 sequences seems to influence STAgR efficiencies. If a certain construct could 
not be obtained, a simple interchange of the gRNA’s sequential order could often solve this 
problem.  
One concern while designing this technique was that the repetitive character of the STAgR 
constructs could oppose a problem for the transcriptional machinery. A multitude of similar 
promoters in close proximity could lead to promoter skipping and therefore lead to 
imbalanced expression of the individual transcripts. RNA Polymerase III transcription 
termination is dependent on a oligo(dT) stretch on the non-template strand (Arimbasseri, 
Rijal, and Maraia 2013). To prevent potential read-through of RNA Pol III and creation of 
non- separated multiple gRNA transcripts each expression cassette was equipped with a pair 
of oligo(dT) termination cassettes. These precautions have proven to be effective, as I could 
show that each gRNA is transcribed to a functional molecule using a genetic assay using 
WTCas9 and a gRNA targeting the open reading frame of the fluorescence protein GFP. By 
providing WTCas9 with a variety of STAgR constructs in which this gRNA was located on 
different positions of four different constructs, I showed that each single gRNA of a 4x 
STAgR constructs is expressed at similar levels. This is crucial as the functionality and the 
effect of CRISPR, as a bipartite system is highly dependent on its two components. If the 
amount of Cas9 or dCas9 effector fusion is stable in a system, the number of different gRNAs 
could limit the quantity of Cas9 for each single target site. Further, if gRNAs are differentially 
represented in a system, the amount of Cas9 effector would be highly variable for the 
different targeting sites. This may not be very crucial for WTCas9 approaches as the induction 
of doublestrand breaks and indel mutations can be a unique event in a cell. For transcriptional 
or epigenomic engineering approaches however, this may be rather significant as the binding 
of the two Cas9 versions seems to be different. WTCas9 has to undergo a conformational 
change before DNA cleavage (Nishimasu et al. 2014). This only occurs after PAM 
recognition, pairing of the seeding sequence and extensive binding of the gRNA to its 
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genomic complement (X. Wu et al. 2014). dCas9 however does not require extensive binding 
of the full sequence and is already bound after PAM recognition, DNA melting and the 
alignment of the seeding sequence, making it more likely to bind off- target sites and thereby 
reducing the amount of dCas9 available at the on- target site (X. Wu et al. 2014). I could 
further show that gRNA multiplexing is beneficial for transcriptional activation compared to a 
pool of single gRNA plasmids. If a cell obtains a multiplexed gRNA vector, the overall 
amount of dCas9 effector has to be subdivided over more targeting sites. The technical 
limitations of an e.g. transfection makes it more efficient to deliver one single plasmid with all 
targeting information than multiple plasmids with one gRNA sequence each.  
The advantages and the potential of convenient gRNA multiplexing strategies are obvious. 
Therefore, other labs have also developed and published gRNA multiplexing strategies. Some 
of them are based on the sequential activity of Type IIS restriction enzymes called Golden 
Gate Cloning. These enzymes cut outside of their recognition sequences to create 4bp 
overhangs which can be used to assemble multiple fragments (Engler, Kandzia, and 
Marillonnet 2008). Golden Gate Cloning-based strategies may share some advantages with 
STAgR cloning but need multiple rounds of cloning to generate desired vectors. This can take 
up to two weeks of time (Lowder et al. 2015; Sakuma et al. 2015b; Vad-Nielsen et al. 2019). 
Using PCR to generate building blocks does save a tremendous amount of time, however it is 
only fair to mention that the end-product requires sequencing of the assembled gRNA 
cassettes as PCR can introduce errors. Modern polymerases have been engineered to be 
highly efficient and therefore PCR- induced errors occur extremely rarely. This strategy has 
also been adapted to Golden Gate cloning to great success, assembling 9 different gRNA 
cassettes in one reaction and published shortly after STAgR cloning (Zuckermann et al. 
2018).  
2. dCas9 based methylation tools 
The establishment of STAgR provided a fundamental basis for various scientific approaches 
using transcriptional as well as epigenomic engineering. To find evidence of a causal 
connection between DNA methylation and disease development, I found that there is a 
necessity to generate novel epigenomic engineering DNA methylation tools. Previous studies 
already showed that dCas9-based DNA methylation is possible (Amabile et al. 2016; X. S. 
Liu et al. 2016a; Stepper et al. 2017a; Vojta et al. 2016a). Even if methylation could be 
induced in targeted attempts, it spread over a wider area. This and the fact that not only site 
specifically, methylation was raised but overall high off- target effects could be monitored, 
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limits the utility of these systems. Site specific methylation would be necessary to assess the 
effect of DNA methylation at a specific locus. Furthermore, as the methyltransferases are all 
derived from and used in mammalian systems, there could be potential host factor 
interference or interaction with the engineering tools. Therefore, I tested viral (M.CviPI), 
bacterial (M.SSS1) and plantal (DNM1a and DRM2) methyltransferases for the use in human 
and murine cell systems. One of the generated methyltransferases (M.SSS1) was published 
during the execution of this thesis. Lei et al. showed that their version of dCas9’M.SSS1 
could be engineered to be more centralized and more efficient in its de novo methylation than 
any other tool published before (Lei et al. 2017a). This suggests that methyltransferases 
derived from different species could hold a potential advantage over mammalian derived 
ones.  
To test their methylation capacity, those unusual methyltransferases were applied in a variety 
of transcriptional and molecular assays. The first assays which were conducted were based on 
the fact that methylation can be a hallmark of promoter silencing, especially artificial 
promoters like CMV and CAG (Y. Zhou et al. 2014). Furthermore, methylation of the CpG 
island of the promoter of the long non coding RNA Airn was shown to be responsible for 
gene silencing of the maternal copy (Koerner et al. 2012; Latos et al. 2009; Stefan H Stricker 
et al. 2008). Targeted methylation of this locus therefore was thought to be able to manipulate 
Airn expression directly. I chose this locus as a further potential target for the 
methyltransferase tools and as readout for their potential methylation capacity. I did not only 
monitor Airn RNA levels but also generated a reporter construct which when methylated was 
hypothesized to reduce transcription of subsequent gene and therefore show a loss of 
fluorescence intensity. Both assays however did not give clear indications of de novo 
methylation. To have a better view at the molecular level, two different loci have been 
analyzed by bisulfite sequencing after targeting with the constructed methylation tools. In my 
experiments, not even the published positive controls DNMT3a and DNMT3a3l induced de 
novo methylation of the analyzed loci.  
There are several possible explanations for the failure of these approaches. Expression of the 
constructs was confirmed by immunohistochemistry stainings of dCas9 (data not shown). 
Furthermore, time plays a crucial factor in de novo methylation, as reportedly targeted 
methylation by dCas9’DNMT3a can take up to five days to be detectable (Vojta et al. 2016b). 
Others showed that with different methyltransferases, like dCas9’MQ1 or dCas9’DNMT3a3l, 
this effect can be rather immediate (Lei et al. 2017; Stepper et al. 2017). The conducted 
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experiments were all in a timeframe of two to seven days. Targeted methylation could also be 
dependent on the targeted loci. Preferred targets of previously conducted studies were 
promoter regions with CpG islands (Vojta et al. 2016). As the chosen target, the Airn 
promoter harbors a CpG which can be methylated during development, it was rather 
surprising that not even positive controls resulted in de novo methylation. It could be that the 
Airn CpG or the promoter of Ube2s are too tightly regulated by the host cell and that any de 
novo methylation could be countered by either de-methylation or cells whose loci were 
successfully methylated simply died. To rule out any cell type specificity the experiments 
have been repeated with another murine cell line (N2a) (data not shown). None of the 
conducted experiments showed any neither positive nor conclusive result. 
3. Alzheimer’s diseases associated differentially methylated positions 
Alzheimer’s disease is undoubtedly one of the biggest burdens of modern society. As public 
attention rises, more and more studies have looked into genomic alterations with genome 
wide association studies to find hints for causes of Alzheimer’s disease (Lambert et al. 2013). 
These studies could even identify high risk genes, however only a small proportion of 
Alzheimer’s disease patients develop those familial forms. As these studies failed to explain 
the underlying risk for AD genetically, it was postulated that epigenetic variation could play a 
significant role in disease development (Ertekin-Taner 2010). Notably, two epigenome wide 
association studies independently identified a set of differently methylated positions which 
were found to be hypermethylated in two different Alzheimer’s disease cohorts (De Jager et 
al. 2014; Lunnon et al. 2014). De Jager et al. and Lunnon et al. provide data which shows a 
correlation between the differentially methylated positions and Alzheimer’s disease 
progression, suggesting that there potentially is a causative relationship. The five significant 
hits reported by both studies were differentially methylated positions in close proximity to the 
genes of RHBDF2, RPL13, C10orf54- CDH23 and ANK1 (Fig. 5). Network analyses even 
revealed a connection of some of these genes to known Alzheimer’s risk genes, supporting the 
idea that the hypermethylation of these DMPs in not only a result of early disease 
development but may be a cause.  
I was planning to test this putative causal relationship by manipulating the differentially 
methylated positions with epigenomic engineering and link these methylation marks to 
potential Alzheimer’s disease indicators. I reasoned it would be best to manipulate these 
marks in cells which allow a subsequent differentiation in disease-relevant cell types. Hence, 
initial experiments were conducted in a variety of human embryonic neural stem cell lines 
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(Sun et al. 2008). The absolute changes in methylation levels were not reported in the EWAS 
studies and an access to raw data was not given. Therefore, I first analyzed the methylation 
level at the loci of interest. Surprisingly, all five loci were already methylated to a high degree 
in all three neural stem cell lines analyzed. Similarly, iPSCs and in vitro differentiated 
neurons and astrocytes from three different genetic backgrounds all showed high methylation 
levels at the analyzed loci. To rule out a potential in vitro artifact, I analyzed the buffy coat 
(mixture of leukocytes and thrombocytes) of human blood and post mortem collected human 
cortical tissue by bisulfite sequencing. All of these samples displayed high methylation levels 
(above ~80%) comparable to analyzed in vitro derived samples. This was further confirmed 
by analysis of the antisense strand of all samples, displaying minor variations but overall high 
methylation levels.  
As the initial paradigm was to raise the methylation levels at those loci and see if they have 
influence on measurable Alzheimer’s disease characteristics, I reasoned that the already high 
methylation levels at the DMPs do not leave any room for further increase and significant 
differences between patients and healthy individuals are likely too small to indicate causality. 
Even if both studies delivered convincing evidence for an association of differential 
methylation and Alzheimer’s pathology, limitations remain (Lord and Cruchaga 2014). Both 
studies utilized Illumina’s HumanMethylation450 platform for quantifying methylation levels. 
While these studies were conducted, this platform was the gold standard to determine 
genome-wide methylation levels. Technical restrictions of this array do not allow the 
investigation of areas which are not part of the pre-designed probe set. This means that overall 
DeJager and Lunnon only looked at 2% of all CpGs in the human genome. This could mean 
that disease-relevant loci might have been missed. Furthermore, this technique does not allow 
distinguishing between methylated and hydroxymethylated CpGs (Fig. 2). As those two DNA 
modifications have been reported to possess contradictory effects on gene regulation, the 
statement about the methylation levels of the DMPs and the potential outcome for gene 
regulation of genes nearby, could be the exactly the opposite (Coppieters et al. 2014). EWAS 
are also highly dependent on the composition of the analyzed tissue. The brain is composed of 
various cell types, and slight variation in cell composition could be mistaken for epigenomic 
changes. This heterogeneity can be compensated by utilizing cell sorting techniques to be able 
to isolate and analyze specific cell types. In these specific epigenomic changes can be linked 
to distinct populations. Technical advances like single- cell epigenomic profiling will 
presumably ameliorate this problem (Kelsey, Stegle, and Reik 2017).  
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Even if EWAS hold a tremendous potential for unraveling epigenomic miss-regulation in 
diseases, reported hits have to be critically examined. EWAS hits should be subsequently 
validated by epigenomic engineering to prove causality and not only hypothesize about it. 
Moreover, EWAS should be seen as a supplementary method to fully elucidate molecular 
miss-regulation in disease. Recent advances in single cell transcriptomics have proven to 
effectively being able to identify transcriptionally distinct subpopulations in Alzheimer’s 
disease samples (Mathys et al. 2019). This allows to reveal transcriptional alterations in 
specific cell populations and to link these to AD pathology. Like this, alternate transcriptional 
profiles can be identified which emerge early during pathogenesis and reveal new risk genes 
whose miss- regulation could contribute to disease development. These miss-regulated genes 
could then subsequently be epigenetically analyzed to further elucidate possible reasons for 
miss-regulation and how to revert them. 
4. Utilizing CRISPR for subtype specific transcriptional manipulation 
Utilizing CRISPR based transcriptional activators for neuronal reprogramming holds great 
potential. The bipartite nature of these tools and its dependence on providing the target 
information by small RNA molecules simplify simultaneous targeting and activation of a 
large number of endogenous genes. Entire gene regulatory networks can be manipulated to 
control cellular fate. With STAgR, I created a multiplexing strategy which made these 
approaches simpler. Because of the vast variety of different neuronal types common in the 
brain, direct reprogramming to specific subtypes is still one of the biggest challenges. Lost 
neurons after traumatic brain injuries or as a cause of neurodegenerative diseases should be 
replaced with the subtype lost. Only if this milestone can be reached, direct reprogramming 
will be applicable as a replacement therapy. Huge efforts in single-cell transcriptomics have 
been made to identify factors which drive these specific fates in various brain structures 
(Chen et al. 2017; Delile et al. 2019; Loo et al. 2019; Telley et al. 2016; Zeisel et al. 2015). 
These datasets help to shortlist transcription factors potentially relevant to drive a specific 
cellular fate. I have chosen a range of factors which was thought to orchestrate a cell to the 
subtype of upper layer callosal projection neurons. These factors were Satb2, Cux1, Cux2, 
Brn2, Nurr1, Bhlhb5, Lhx2, Tle2, and Mef2c. I generated gRNAs which targeted the 
promoter regions of each of these genes. Different transcriptional activators have been tested 
over the time, to find the best system. I confirmed dCas9’VPR to be the more potent 
transcriptional activator over dCas9’VP64 (Chavez et al. 2016). Furthermore, targeting with 
two gRNAs can result in a synergistic effect on transcriptional activation. This is in line with 
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other publications, showing that induction of transcription seems to be dependent on the 
amount of programmable transcription factors targeted to a transcription start site. 
Consequently, systems which accumulate artificial transcription factor molecules at a 
promoter region can be more efficient than simple single transcription factor fusion constructs 
(Chavez et al. 2016).  
Throughout the conducted experiments, I noticed that not all genes are equally activated 
transcriptionally in one cell type. I generally observed three classes of genes. The first group 
does not respond significantly to transcriptional activation. Multiple gRNA sets, which 
targeted different annotated transcription start sites, were not able to increase mRNA levels 
indicating that other barriers cause this unresponsiveness. Another group of genes showed 
minor (3 to 10-fold) transcriptional induction after targeting with dCas9’VPR. The last group 
of genes is highly responsive as mRNA levels could be raised by up to thousand fold 
compared to endogenous levels. Interestingly, these groups of genes were not always 
consistent in the different host cells I utilized. This suggests that individual genes can react 
differently in one cell type or the other. Each individual cell type may tightly control 
expression of certain genes, which overrules dCas9’VPR. Which specific mechanisms 
underlie this tight control, still needs to be elucidated. Studies suggest that chromatin 
modifications could play such a role (Luz-Madrigal et al. 2019). Indeed, we have experienced 
that a targeted de- methylation can lead to an increase in transactivation by dCas9’VP64 
(Baumann et al. 2019). This further emphasizes the potential of combining transactivators and 
chromatin modifier orchestrated by gRNA expression of a highly customized gRNA 
construct.  
5. Utilizing CRISPR for in vivo reprogramming 
With the establishment of the functional activator reporter (Section B3.4), I thought to have 
found a solid way to target multiple endogenous promoters in vivo and follow the activation 
of subsequent genes and a potential transdifferentiation. However, this system did not 
translate well into viral vectors which set me back to the use of conventional fluorescence 
reporters. Even if a lot of effort has been expended to optimize and simplify the use of dCas9 
transcriptional activators, I encountered various difficulties to translate and utilize this system 
in in vivo experiments. Undoubtedly, the advantages of dCas9 activator systems have been 
thoroughly discussed. However, if there is a dependency on viral vectors to deliver all 
components, one also faces size limitations as the most competent dCas9 transactivators can 
exceed the packaging limit of one single lentivirus (Kumar et al. 2001). Even after various 
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attempts to utilize ways to split dCas9 activators on two different lentiviral particles, the titers 
have not been high enough for in vivo usage (Tanenbaum et al. 2014; Zetche, Volz, and 
Zhang 2015). The chance to work with a dCas9 activator transgenic mouse line vastly 
simplified these experimental paradigms.  
If this system is able to help orchestrating the process of subtype specific reprogramming still 
remains an open question and could not be answered during the conduct of this thesis. Next 
experiments will be in vivo injections of gRNA and NeuroD1/ NeuroD4 packed viral particles 
into the somatosensory cortex after brain injury. Crossing the dCas9 activator mouse line, 
whose transgene expression is silenced with a loxP-STOP- loxP cassette with mice expressing 
Cre recombinase under the murine promoter of aldolase, limits expression of the activators to 
astrocytes. After a given amount of time, cells which obtained gRNAs and pro- neural factors 
should be analyzed in regard to their morphology, cell type specific and especially subtype 
specific markers like NeuN, CUX1 or CTIP2 (Mattugini et al. 2019).  
 
Should this approach prove successful, one should use the tremendous amount of 
transcriptomic data to identify potential factors defining other neuronal subtypes to push the 
specificity of direct reprogramming.  
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D. Materials and Methods 
1. Materials 
1.1 Hard- and software 
This work was written on an Acer Aspire V Nitro running Windows 10 Professional and 
using the text processing software Microsoft “Word” 2010. Images were processed with 
GIMP (GNU Image Manipulation Program) Version 2.6, ImageJ Version 1.48p (Wayne 
Rasband, USA), “Inkscape” Version 0.91 (Free Software Foundation, Inc., Boston, USA) and 
Zeiss Zen blue Version 2.6 (Carl Zeiss Microscopy GmbH, Jena, Germany). Nucleic acid as 
well as protein sequences were analyzed using “Snapgene” Version 3.3 (GSL Biotech, 
Chicago, USA) or “Serial Cloner” Version 2.6.1 (Serial Basics). Literature and database 
searches were performed with the online tool provided by the National Center for 
Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/). 
1.2 Chemicals, reagents, media and supplements 
All experiments done during this work were performed using chemicals of analytical grade 
and unless otherwise noted, are listed in Table 1. 
Table 1│ List of used reagents and chemicals plasmids for different expression systems. 
Name Catalogue Manufacturer 
6x DNA loading dye R0611 Thermo Fisher Scientific 
Agarose 870055 Biozym, Oldendorf 
Aqua poly mount 18606 Polysciences 
Bovine Serum Albumine A2153-1KG Sigma-Aldrich 
DAPI Nuclear Staining Dye 1351303 Bio-Rad Laboratories 
ECL Luminol Reagent sc-2048 Santa Cruz Biotechnology 
Ethanol, 99.9% 9065.2 Carl Roth 
GeneRuler 1kb DNA ladder SM0313 Thermo Fisher Scientific 
Gibson Assembly Master 
Mix 
E2611 NEB 
HotStar Taq 203203 Qiagen 
Methanol 34860-1L-R Sigma-Aldrich 
Nuclease-free water AM9932 Life Technologies 
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Paraformaldehyde 158127-5G Sigma-Aldrich 
Poly-D-Lysine P6407-5MG Sigma-Aldrich 
Phusion DNA Polymerase 
Master Mix 
M0531S NEB 
PowerUp
TM
 Sybr Green 
Master Mix 
A25742 ThermoFisher Scientific 
SYBR Safe DNA Gel Stain 5001208 Life Technologies 
Triton-X 100 T8655.1 Biomol 
Bovine serum albumin A9418 Sigma-Aldrich 
Accutase A6964-100ML Life Technologies 
BDNF PHC7074 Gibco 
Blasticidin S R21001 ThermoFisher Scientific 
Cryotubes 10577391 Thermo Fisher Scientific 
DMSO D5879-100ML Sigma-Aldrich 
EGF 78006 Stemcell Technologies 
Fetal calf serum C8056-500ML Sigma-Aldrich 
Hygromycin B 10687010 ThermoFisher Scientific 
Lipofectamin® 2000 11668027 ThermoFisher Scientific 
Puromycin A1113803 ThermoFisher Scientific 
 
1.3 Antibodies 
Table 2│ List of used primary and secondary antibodies. 
Antibody Antigen 
Non-commercial primary antibodies  
rat IgG2a Cas9 Clone 8641-1 spCas9 
Commercial primary antibodies Source / Product# / Lot# 
mouse IgGI anti- GFAP Sigma- Aldrich / G3893 / 083M4785 
chicken anti- GFP Aves Labs Inc. / GFP- 1020 / GFP697986 
rabbit anti- RFP Rockland / 600-401-379 / 33235 
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commercial secondary antibodies  
Alexa Fluor 546 goat- anti- rat IgG Invitrogen / A11081 
Alexa Fluor 488 goat- anti- mouse IgG Invitrogen / A11039 
Alexa Fluor 546 goat- anti- rabbit IgG Molecular Probes / A21207 
Alexa Fluor 647 goat- anti- mouse IgG1 Invitrogen / A21240 
 
1.4 Plasmids 
Plasmids used in conducted experiments were part of the Stricker laboratory plasmid library.  
Table 3│ Used plasmids for different expression systems. 
Insert Reporter Backbone /Name 
hU6_gRNAScaffold Neomycin MLM3636/ gRNA 
Neo 
hU6_ SAM loop Neomycin MLM3636/ SAM 
Helper 
hU6_gRNAScaffold GFP MLM3636/ green 
STAgR 
hU6_gRNAScaffold TdTomato MLM3636/ red 
STAgR 
hU6_gRNAScaffold BFP MLM3636/ blue 
STAgR 
hU6_gRNAScaffold/miniCMVGFP GFP MLM3636/ 
Functional Activator 
Reporter 
Lenti_gRNA vector GFP plKO1 
dCas9’VP64 Hygromycin/GFP pcDNA3 
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dCas9’VPR Hygromycin/GFP/ 
RFP 
pcDNA3 
dCas9’DNMT3a Hygromycin/GFP pcDNA3 
dCas9’DNMT3a3L Hygromycin/GFP pcDNA3 
dCas9’SSS1 Hygromycin/GFP pcDNA3 
dCas9’CviPI Hygromycin/GFP pcDNA3 
dCas9’DMN1a Hygromycin/GFP pcDNA3 
dCas9’DMR/ARATH Hygromycin/GFP pcDNA3 
Lenti_dCas9_SunTag - plKO1 
1.5 Oligonucleotides 
Oligonucleotides have been used to amplify sequences of interest for Gibson cloning, Sanger 
sequencing or quantitative RT PCR. Oligonucleotides for Gibson cloning have been designed 
using the NEBBuilder (https://nebuilder.neb.com/). Primer3Plus was used for qPCR primer 
design (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi) wheras Bisulfite Sequencing 
primer were designed with MethPrimer 2.0 (Urogene, http://www.urogene.org/cgi-
bin/methprimer2/MethPrimer.cgi). All primers were purchased either from ThermoFisher 
Scientific or Metabion.  
Table 4│ Used oligonucleotides. 
Oligonucleotide Sequence Usage 
8xgRNASeq_fwd1 GAGACGCAGGGAGGGAT Sequencing 
8xgRNASeq_fwd2 AGCGGGCGAAGCCAGTGA Sequencing 
8xgRNASeq_rev1 CGTTTGGGGAAGGCCAC Sequencing 
DNMT3A3L_SeqPrimer TCTGGAGCACGGCAGAATAG Sequencing 
GFP Seq fwd GGCAAGCTGACCCTGAAGT Sequencing 
GFP Seq rev TCTAGATCCGGTGGATCCC Sequencing 
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GFPbeginningSeq_rev TCCAGCTCGACCAGGATG Sequencing 
hPGK_seqF GGTCTCGCACATTCTTCAC Sequencing 
p65_seqR GCTGCTGAAACTCAGAGTTGTC Sequencing 
STAgR_minimalCMVseq_fwd CAAGGTCGGGCAGGAAGA Sequencing 
StAgR_seq_fwd1      GAGTTAGGGGCGGGACTATG Sequencing 
StAgR_seq_fwd2        ACTGGATCCGGTACCAAGG Sequencing 
AIRNmid_fwd CTTCCTCAACCTGCCTGAAG qPCR 
 AIRNmid_rev GTTGTCGGTGTCGAGGTTTT qPCR 
Bhlhe22 _qPCR_fwd CCGAGTCCAGACGTTCACTT qPCR 
Bhlhe22 _qPCR_rev GCCCGTGTAGATCGTGTCAT qPCR 
Brn-2 _qPCR_rev GCCTCTGAGTCCAATCCCGC qPCR 
Brn-2_qPCR_fwd GCTGGTTGATGGGTCCGGAA  qPCR 
Cux1_qPCR_fwd GCTGAGATACGCTTAGCACTTGAGT qPCR 
Cux1_qPCR_rev CGGGTCTGTCCAAACCTCTATACA qPCR 
CyclophilinA_fwd CAAAGCCACGGATCAATCTT qPCR 
CyclophilinA_fwd GACGTGTTGCGCACTTAACG qPCR 
CyclophilinA_rev CCCGGGAATAGTGAAACTGA qPCR 
CyclophilinA_rev ACGACATAGATTGGGCTTAATGCT qPCR 
Lhx2_qPCR_fwd CACATCCTCAAGCCTCCAAGAA qPCR 
Lhx2_qPCR_rev AAAGGAGACAGTCTTGGCCAGTGT qPCR 
mCux2_qPCRfwd CCCACCGTGTTCTTCGACATT qPCR 
mCux2_qPCRrev GGACCCGTATGCTTTAGGATGA qPCR 
Mef2c_qPCR_fwd TTTCCTCAAATGCCCCAAG qPCR 
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Mef2c_qPCR_rev TTTCTGTCTCCTGTTACAAAACCA qPCR 
mSatb2_qPCRfwd CCTCAAGACGAACACCGTCAT qPCR 
mSatb2_qPCRrev GCGCATCCTGGACCTGTAGT qPCR 
Tbr1_qPCR_fwd CCTACTACAACGGCGTGGGCACTGT  qPCR 
Tbr1_qPCR_rev GTCACGATCCAGGTGTTCAGCATCG qPCR 
Tle2_qPCR_fwd GACCAGTTCCGCCCGTTT qPCR 
Tle2_qPCR_fwd CACATCCTCAAGCCTCCAAGAA qPCR 
Tle2_qPCR_rev GCAAGACCACAAAATATTGAAAAGA
C 
qPCR 
Tle2_qPCR_rev AAAGGAGACAGTCTTGGCCAGTGT qPCR 
AldoCreGeno_fwd CCTGTCCCCTTGCACAGTAG Genotyping 
AldoCreGeno_rev CGGTTATTCAACTTGCACCA Genotyping 
Cas9 F TCTTCGGCAACATCGTGGACG Genotyping 
Cas9 R   CGGTTCTTGTCGCTTCTGGTCAGCA Genotyping 
 
1.6 gRNA Sequences 
gRNAs used during the conducted experiments are listed in Table 5.  
Table 5│ gRNA sequences 
Target Sequence 
Cux2 gRNA1 GGGGAGCACGGAGAGCGCGC 
Cux2 gRNA2 GACGGCGCCTGGACTGGCGG 
Cux2 gRNA3 GGGTCCAGCCCGGGTGTTGG 
Cux2 gRNA4 TTTACGGTCCCCGTCGCCCG 
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Cux2 gRNA5 TCTGAATCGATATAAAGAGG 
Cux2 gRNA6 ACAGGCCTGTCCAGGTGACA 
Satb2 gRNA1 GCGGTGGACCAGTCTGGCTT 
Satb2 gRNA2 CCTGTGCCTCCTCCGCAGCC 
Satb2 gRNA3 CACCGAGAAAAGTTGCTCCG 
Satb2 gRNA4 GAAGTGGCCTTCCCCAAACG 
Cux2 gRNA7 TCTCTCTCTCTCGTTGCAGA 
Cux2 gRNA8 ACAAGTTTCTGTAACTTACA 
Cux2 gRNA9 CATTTTTGCCCTTAGGCACT 
Tle2 gRNA1 GCGCGCGCCTCTGGAGCCGT 
Tle2 gRNA2 TTGCCTAATTTCTCTCCCCC 
Tle2 gRNA3 TGGAACCGAAGAAGCAGAGC 
Lhx2 gRNA1 GAGACGCAGGGAGGGATCCG 
Lhx2 gRNA2 GGAGCGGGCGAAGCCAGTGA 
Lhx2 gRNA3 TCCTCAACCCCAGGTTCCAG 
Lhx2 gRNA4 GCCCCAGACCGAAGCCCAGA 
Lhx2 gRNA5 CTTCAATTCTCCCAGTGGCT 
Lhx2 gRNA6 CGCTTGGGTAGCGTTGCGCG 
Mef2c gRNA1 TCTTGTTCCAAGATTATTCT 
Mef2c gRNA2 ATTTTGGATAGACTTCCGAT 
Tbr1 gRNA1 GCAGTGGTCACAAAGCTTAA 
Tbr1 gRNA2 GACGATCATGGCAAATTGAA 
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Bhlhb5 gRNA3 GCAGTTGTTGGGTTACTAAC 
Bhlhb5 gRNA4 TGCTGCCTGTCTTCAGACCT 
Cux1 gRNA1 GCGCGCGGGAAAAAGGGTGA 
Cux1 gRNA2 GCGCCCTTTAGGTGAGCTGC 
Cux1 gRNA3 CGTGAAAGTGACTGCGGAGC 
Cux1 gRNA4 ATTGTCAACCGGTGTCGCCC 
Cux1 gRNA5 GCCCGCCTGCTGCCTCCTGG 
Cux1 gRNA6 TTCGGACTCCATGGCTGAGG 
Brn2 gRNA1 GGAGAGAGCTTGAGAGCGCG 
Brn2 gRNA2 GCGGTATCCACGTAAATCAA 
Brn2 gRNA3 CCAATCACTGGCTCCGGTC 
Brn2 gRNA4 GGCGCCCGAGGGAAGAAGA 
Brn2 gRNA5 GGGTGGGGGTACCAGAGGA 
Cited2 gRNA1 AGCTTACTCGCAATAACAAG 
Cited2 gRNA2 TTTGATTAAACCACACCAAG 
NeuroD1 gRNA1 CCGTGAGCTGAGCAACGAGC 
NeuroD1 gRNA2 TGGACGCGTGCGCGATTGCG 
NeuroD1 gRNA3 AGACCATATGGCGCATGCCG 
CAG Promoter gRNA1 TTTCCATTGACGTCAATGGG 
CAG Promoter gRNA2 ATTATTTTGTGCAGCGATGG 
CAG Promoter gRNA3 CGGGAGGGCCCTTTGTGCGG 
CAG Promoter gRNA4 TTTTATGGTAATCGTGCGAG 
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CAG Promoter gRNA5 GCCTCGGGGCTGTCCGCGGG 
AIRN Promoter gRNA1 GGGTAGGATTCCGTTGCAAG 
AIRN Promoter gRNA2 GAACTACACGAGGGCCGATA 
AIRN Promoter gRNA3 GACCTGATCCGCGGTTTGCG 
AIRN Promoter gRNA4 GCACAAGGGCAGGGTTCCGA 
TTN gRNA 1 GAGCCGGGCTGTAAGGATGT 
TTN gRNA 2 GCTAAATTTAGCCTTTCAGAAG 
ActcI gRNA 1 GGCTCCAAGAATGGCCTCAG 
ActcI gRNA 2 GGGAGGGGCAGGCCAGCAAG 
Ube2s gRNA1 AGGTGGGCCTGAGGCCTAGC 
Ube2s gRNA2 GTCCGAGGAGTGCAGGAAGG 
miniCMV Reporter Plasmids ACCAATTCAGTCGACTGCCC 
miniCMV/teton/CMV  
„uni CMV“ 
GTAGGCGTGTACGGTGGG 
2. Microbiological methods 
2.1 Strains 
For molecular cloning and plasmid production the E. coli XL-1 Blue strain 
(Stratagene/Agilent Technologies) was used.  
Genotypes: 
E. coli 
 
Top10 - F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 
Δ(ara-leu)7697 galE15 galK16 rpsL(Str
R
) endA1 λ
- 
 
STBL3 - F- glnV44 recA13 mcrB mrr hsdS20(rB-, mB-) ara-14 galK2 lacY1 proA2 rpsL20 
xyl-5 leu mtl-1 
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2.2 Media 
LB medium: 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
LB agar 
LB medium + 1.5% (w/v) agar 
SOC Medium 
2% (w/v) tryptone 
0.5% (w/v) yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
2.3 Cultivation of E. coli 
The different E. coli strains were cultivated in LB medium at 37°C and at approximately 
200 rpm. LB agar dishes were incubated at 37°C. Selection of successfully transformed 
clones was done by adding antibiotics to either LB medium or LB agar. Used antibiotics were 
Ampicillin (100 µg/ml) and Kanamyin (50 µg/ml).  
2.4 Transformation of E. coli Top10 and Stb3 
The frozen and chemically competent bacteria were thawed on ice. 50- 200 ng of plasmid 
DNA were added to 20- 50 µl bacterial suspension and incubated on ice for at least 20 min. 
After heatshocking the cells at 42°C for 45 s, the cells were chilled on ice for additional 2 
min. Then 10x the volume of used bacterial suspension LB (for XL1 Blue/ Rosetta 2 DE3+) 
or SOC (for DH10Bac) medium was added and the suspension was incubated at 37°C for at 
least 20 min on 200 rpm. The cells were then plated onto LB agar plates containing antibiotics 
and incubated at 37°C overnight or LB medium containing antibiotics was inoculated, 
directly.  
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3. Molecularbiological methods 
3.1 Isolation of plasmid DNA from E. coli Top10 / STBL3 
Depending on the desired amount of isolated DNA, 2- 300 ml LB (+ corresponding antibiotic) 
were inoculated with the previous transformed E. coli strain and incubated at 37°C for at least 
12h. The cells were harvested and centrifuged at 4000g, 4°C and for 15 min. Alkaline lysis 
and DNA purification was done by using anion exchange columns, which were as well as the 
different used buffers, provided by ThermoScientific (Mini/Maxi-Kit) and according to the 
manufacturer’s protocol.  
3.2 Determination of DNA concentrations in solutions 
DNA concentrations in solution were determined by measuring the optical density at a 
wavelength of 260 nm. This was done using a ND-1000 spectrophotometer (PeqLab). 
OD260nm= 1 correspond to a concentration of 50 µg/ml double-stranded DNA. The purity of 
DNA was determined by the quotient of absorptions at 260 and 280 nm.  
3.3 Restriction digestion of DNA 
Sequence specific enzymatic restriction digestion of DNA was done using site-specific 
endonucleases from NEB (Frankfurt a. M., Germany). 200 ng to 1 µg of DNA was diluted in 
enzyme specific buffers and incubated with 1 to 4 units of endonuclease for 1h at 37°C. The 
enzymes were either inactivated at 65°C for 20 min or removed by gel electrophoresis (4.3.4) 
as well as appropriate purification kits.  
 
 
3.4 Separation and analysis of DNA fragments by agarose gel electrophoresis 
10x TBE buffer 
0.5 M Tris 
1.3% (v/v) H3BO3 
20 mM EDTA 
6x DNA loading buffer 
50% (v/v) glycerol 
0.02% (w/v) Orange G 
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Solutions with different sized DNA molecules have been supplemented with 6x DNA loading 
buffer (to 1x) and separated by loading onto 1% (w/v) agarose gels containing 0.5 µg/ml 
SYBR Safe (Invitrogen) in TBE. The gels were run at 120 V for 25 to 40 min. Separated 
DNA fragments were visualized with a UV transilluminator at 324 nm and size analyzed by 
using 1kb ladder (ThermoFisher Scientific).  
3.5 Gelextraction of DNA fragments 
For gel extraction of DNA fragments, buffers and anion exchange columns, provided by 
ThermoScientific (Gel Extraction Kit) were used according to manufacturer’s protocols. 
Elution of DNA was done in 15 µl ddH2O.  
3.6 DNA Purification with AMPure Magnetic Beads 
After PCR or enzymatic digestion, DNA samples were purified with magnetic AMPure XP 
Beads. Per 1 µl sample, 1.8 µl AMPure XP beads were added and the solution was incubated 
for 2 min on RT. The beads and the DNA fragments were separated from the residual liquid 
using a magnet and then washed twice with 70% Ethanol. The pellet was air dried and 
dissolved in 15-20 µl H2O to release the bound DNA fragments. Purified DNA was separated 
from the beads using a magnet and transferred to a new 1.5 µl reaction tube for subsequent 
usage. 
3.7 Dephosphorylation of DNA-fragments 
To avoid religation of digested linearized vectors, the 5’- phosphate was removed by addition 
of 1 U phosphatase (NEB, “Antarctic Alkaline Phosphatase”, AAP) together with the 
appropriate reaction buffer. The solution was incubated for 30- 45 min at 37°C and the 
enzymes were removed by either AMPure XP beads or by gel electrophoresis.  
3.8 Ligation of DNA fragments 
The linearized and dephosphorylated vector was enzymatically ligated with a DNA fragment 
of interest by adding 1 U T4 DNA-ligase. The reaction was performed in a volume of 20 µl 
1x T4 ligation buffer, over-night at 16°C or at RT for 10min to 2h.  
3.9 Gibson Cloning 
If not otherwise indicated all constructs used in this work were generated with Gibson cloning 
(Gibson et al. 2009b).  
 
5x Gibson isothermal reaction buffer 
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25% (w/v) PEG-8000 
500 mM Tris-HCl pH 7.5 
50 mM MgCl2, 
50mM DTT 
5mM NAD 
1mM each of the four dNTPs 
 
1.33x Gibson Master Mix: 
Taq ligase (40u/µl): 50 µl 
5x isothermal buffer: 100 µl 
T5 exonuclease (1u/ul): 2 µl 
Phusion polymerase (2u/ul): 6.25 µl 
Nuclease-free water: 216.75 µl 
Overhang primers for Gibson assembly were designed using the online tool NEBBuilder 
(https://nebuilder.neb.com/#!/) and are listed in 4.1.5. Fragments were generated using 
Phusion High Fidelity DNA Polymerase (NEB) according to manufacturer’s protocol. PCR 
fragments were analyzed by gel electrophoresis and isolated using AMPure XP beads. After 
determining the DNA concentration as described in 4.3.2., DNA fragments were combined in 
a molar vector to insert ratio of 1:3 to a total volume of 2.5µl and 0.5 pmol. 7.5 µl of Gibson 
Master Mix were added and the reaction was incubated at 50 °C for 45 to 60 min. The 
reaction was then transformed into chemically competent bacteria as described in 2.4.  
3.10 STAgR Cloning 
All multiplexed gRNA vectors were generated according to the protocol developed during 
this thesis (Breunig et al. 2018a; Breunig et al. 2018b).  
3.11 single gRNA Cloning 
Expression vectors for single gRNA expression, are all based on the plasmid pMLM3636 
(Addgene plasmid 43860). The vectors were either Neomycin selectable (gRNA_Neo), 
carried a fluorescence marker gene (STAgR_TdTomato or STAgR_GFP) or a minimal CMV 
Promoter Reporter construct. All vectors contained the hU6 Promoter as well as the gRNA 
stem loop (scaffold) or the SAM loop (Mali et al. 2013) separated by an AgeI restriction site, 
which was used for vector linearization. gRNA sequences were ordered as 80bp single 
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stranded DNA oligos, whereas a 5’ overhang (TCTTGTGGAAAGGACGAAACACCG) and 
a 3’ overhang (GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCT) were added to 
the 20bp protospacer sequence for subsequent cloning. Single gRNA double stranded DNA 
cloning fragments for Gibson cloning were generated by Phusion PCR using 
“LibGen_U6_fwd” and “LibGen_Scaffold_rev” as primers and the corresponding 80bp single 
stranded DNA oligos as template. After PCR gRNA fragments were isolated as describe in 
4.3.6 and used in a Gibson Assembly reaction as described in 4.3.9. The reaction was 
transformed into chemically competent bacteria and incubated for 16h at 38 °C. DNA was 
isolated as described in 4.3.1 and clones were analyzed by Sanger Sequencing using 
“STAgR_seq_fwd2” as a sequencing primer.  
4. Cell biological methods 
4.1 Mammalian cell lines 
The following mammalian cell lines were used. 
Hek 293T  Human embryonic kidney cell transformed with SV 40 large T antigen 
MEF   Mouse Embryonic Fibroblasts derived from embryonic tissue 
N2a Murine neuroblastoma cell line 
P19 Murine embryonic carcinoma cell line derived from embryo- derived 
teratocarcinoma.  
4.2 Cultivation of mammalian cell lines 
Cells were cultivated in DMEM medium (Dulbecco’s modified eagle medium) supplemented 
with 10% (v/v) FCS (fetal bovine serum, Biowest/Sigma) and 1% penicillin/streptomycin 
(10000 U/ml penicillin, 10000 µg/ml streptomycin). Additional supplements for specific cell 
lines are listed in table 6. Cells were grown in a monolayer in cell culture dishes at 37°C and 
an atmosphere containing 5% CO2. Cells were, depending on the cell density, split up to twice 
a week in ratios from 1:4 up to 1:10. To do so, the media was removed and the cells were 
washed with 1x PBS followed by 5 min incubation with 16 µl/cm
2
 Trypsin/EDTA solution at 
37°C. Cells were suspended in fresh DMEM medium, pelleted for 2 min at 300g (Megafuge 
8R, Thermofisher Scientific) and then diluted in an appropriate amount of medium for a 
following distribution on new cell culture dishes.  
Table 6│ Volume of transfection reagents and medium.  
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Cellline Supplements 
Hek293T - 
MEF 10 mM HEPES Buffer Solution 
1 mM Sodium pyruvate solution 
N2a 1x MEM NEAA 
P19 1x MEM NEAA 
 
4.3 Storage of mammalian cells 
For long time storage, cells were trypsinized or resuspended by pipetting, pelleted by 
centrifugation (5 min, 300g) and then resuspended in FCS with 10% (v/v) DMSO. The cells 
were then aliquoted into cryo vials. The vials were slowly frozen in isopropyl at -80°C.  
When reutilized, cells were thawed in a 37°C water bath and pelleted by centrifugation for 
1 min at 300g. The supernatant was removed and the pellet resuspended in fresh medium 
before it was transferred into a cell culture dish. 
4.4 Transfection of mammalian cells 
If not otherwise indicated, cells were transfected using Lipofectamin 2000 (L2K, 
Thermofisher Scientific). All cells were either seeded or cultivated until a cell confluence of 
80% and the media was changed prior to the transfection to the corresponding media but 
without any antibiotics. For each transfection sample, the DNA (appropriate amount can be 
seen in table 7) was diluted in Opti-MEM (Gibco) and mixed gently. Lipofectamine was 
vortexed prior to usage and diluted in another 1.5 ml reaction tube in Opti- MEM. After 
incubation of both tubes for 5 min on RT the diluted DNA was added to the diluted 
transfection reagent and the mix was incubated for 20 min on RT. The full reaction was added 
drop- wise to wells containing cells and medium. 
Table 7│ Volume of transfection reagents and medium.  
Plate Size Volume of 
plating medium 
Volume of 
dilution medium 
DNA L2K 
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24- well 500 µl 2x 50 µl 0.8 µg 2 µl 
12- well 1 ml 2x 100 µl 1.6 µg 4 µl 
6- well 2 ml 2x 250 µl 4 µg 10 µl 
 
4.5 Preparation of primary Astrocyte cultures 
Astrocyte medium 
  DMEM – F12 50:50 (+Glutamax) 
  1% (v/v) penicillin/streptomycin 
  10% (v/v) FCS 
  B27 
  EGF/FGF 
For primary astrocyte cultures animals were taken at postnatal day 5-7. The pups were 
decapitated and the brains were isolated and transferred to a dish with Hank’s Buffered Salt 
Solution (HBSS). After removing the meninges, the two hemispheres were separated and the 
cortical matter was dissected from the underlying striatum as well as the hippocampi. This 
tissue was then transferred to a 15 ml tube with astrocyte medium and dissociated with a 
P1000 by repeatedly pipetting up and down. The cell suspension was then transferred to a 
poly-Lysine coated T25 tissue culture flask and incubated in a cell culture incubator for one 
week before further processing.  
4.6 Transfection of primary Astrocyte cultures 
Cells were seeded one day prior to transfection. Seeding densities can be taken from table 9. 
Before transfection the astrocyte medium was removed and collected in a 50 ml falcon 
(“conditioned astrocyte medium”). The appropriate amount of Opti- MEM was added to each 
well and the cells were put back into the incubator. DNA as well as lipofectamin was diluted 
in Opti- MEM in two separate 1.5 ml reaction tubes, according to table 9, incubated for 5 min 
and then the DNA dilution was added to the transfection reagent dilution. This mix was 
incubated for 20 min at RT and then added drop- wise to the cells. After 4 h the transfection 
mix was removed and the prior collected conditioned astrocyte medium was added to the 
cells.  
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Table 9│ Seeding density and volume of reagents for Astrocytes transfection 
Plate 
size 
Cell 
number 
Volume of 
plating medium 
Volume of dilution 
medium 
DNA L2K 
24 well 60000 300 µl 2x 50 µl 600 ng 0,75 µl 
12 well 100000 600 µl 2x 100 µl 1200 ng 1,5 µl 
6 well 350000 1 ml 2x 125 µl 2000 ng 3 µl 
 
4.6 Indirect immunofluorescence microscopy 
4.6.1 Staining of Tissue Culture on coverslips 
Cells were seeded on poly-l-lysine treated coverslips. Cells were then fixed in 4% (v/v) 
paraformaldehyde (in 1x PBS) for 20 minutes at 37°C followed by permeabilization with 
0.1% (v/v) Triton X-100 (in 1x PBS). Next, cells were blocked in 10% FBS for 30 minutes at 
RT. Cells were then incubated overnight (at 4°C) with the appropriate primary antibodies, 
diluted in 3% BSA (in 1x PBS). Coverslips were then washed with 1x PBS supplemented 
with 0.1% Triton X-100 for 1x 5 min and additionally with 1x PBS for 3x 5 min at RT. 
Primary antibodies were detected using secondary antibodies with fluorophores, diluted in 
0.1% Triton X-100 (in PBS) at 1:1000 and incubated for 2h at RT. Following this, coverslips 
were washed one time with PBS supplemented with 0.1% TX100 (Sigma) and twice with 1x 
PBS only. Finally, DNA was stained with DAPI (1 μg/ml) for five minutes at RT. Coverslips 
were mounted on top of slides using Aqua- Poly mounting medium and stored until further 
analysis.  
4.6.2 Staining of free floating brain slices 
After taking out them out of the storing solution, the brain slices were washed on a shaker 
with PBS for 10 min at RT. The tissue was blocked and permeabilized by incubation in PBS, 
supplemented with 0.5% (v/v) TritonX100 and 10% (v/v) normal goat serum (NGS) for 30 
min to 2 h at RT on a shaker. Primary antibodies were diluted appropriately, in the previous 
described blocking solution. Slices were then incubated overnight at 4°C on a shaker. Brain 
slices are washed 3- times with PBS prior to incubation with secondary antibodies, which are 
diluted 1:500 in blocking solution. Secondary antibodies are left on the slices for 2 h at RT on 
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a shaker. Chromatin is stained with DAPI diluted 1:1000 in PBS for 10 min at RT. The slices 
were then washed another 3 times with PBS and were then mounted on glass objective slides.  
5. Animal methods 
5.1 Mouse strains 
B57BL6/J Aldh1l1-Cre 
B57BL6/J ROSA26_dCas9-VPR_CRKI, carrying a transgene consisting of a CAG Promoter 
followed by a loxP STOP loxP cassette. This loxP STOP loxP site prevents expression of the 
transcriptional activation machinery consisting of the MS2 RNA binding protein fused to the 
transcription factor p65 and heatshock protein HSF1 (Konermann et al. 2014b). This 
transcriptional frame is continued by a P2A sequence and dCas9 fused to VP64, p65 and Rta 
(Chavez et al. 2015). 
B57BL6/J ROSA26_dCas9-VPR_CRKIxAldh1l1-Cre. To provide Cre expression in Aldh1l1 
positive cells.  
5.2 Genotyping of transgenic mice 
 Lysis buffer 
  1 M NaCl 
  1 M Tris/HCl pH 8.5 
  10% SDS 
  0.5 M EDTA 
  10mg/ ml Proteinase K 
Genotyping was performed by PCR on genomic DNA extracted from ear clip biopsies. Ear 
clips were incubated with 0.5 ml lysis buffer at 55°C in a shaker (100 rpm) over night. 
Undissolved tissue was removed by centrifugation at 14000 rpm for 5 min. The supernatant 
was transferred to a new 1.5 ml reaction tube and DNA was precipitated with 0.5 ml 100% 
Isopropanol and pelleted by centrifugation at 14000 rpm for 10 min. After removing the 
residual supernatant, the pellet was air- dried at room temperature for at least 30 min. DNA 
pellets were dissolved in 200 µl 10 mM Tris buffer (pH 8) in a thermomixer at 55°C and 100 
rpm.  
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Primers for PCR reactions are listed in table 10 and PCR compositions as well as PCR 
conditions are listed in Tables 10 and 11.  
Table 10│ Genotyping PCR compostion  
Name Buffer A MgCl2 
(25mM) 
Q- Solution primers dNTPs 
(10 mM) 
Taq H2O 
Aldh1l1- 
Cre 
2.5 µl 2.5 µl 5 µl 0.5 µl 0.5 µl 0.5 µl 11 
µl 
dCas9- VPR 2.5 µl 2.5 µl 5 µl 0.5 µl 0.5 µl 0.5 µl 11 
µl 
 
Table 11│ Genotyping PCR conditions 
Name Aldh1l1- Cre  dCas9- VPR 
1.Initial Denaturation 95°C 2 min 95°C 2 min 
2. Denaturation 95°C 30 s 95°C 30 s 
3. Annealing  58°C 30 s 58 °C 30 s 
4. Elongation 72°C 2.5 min to 2. 35x 72°C 2.5 min to 2. 35x 
5.Final Elongation 72°C 5 min 72°C 5 min 
Fragment size 420 bp 2.2 kb 
5.3 Stereotactic operations 
5.3.1 Anesthesia 
Mice were anaesthetized with an intraperitoneal injection of a mix of Fentanyl (0.05 mg/kg 
bodyweight), Midazolam (5 mg/kg bodyweight) and Medetomidine (0.5 mg/kg bodyweight) 
dissolved in a 0.9% NaCl (a solution called “Sleep”). After surgery the mice were recovered 
from anesthesia with a mix of Buprenorphine (0.1 mg/kg bodyweight), Atipamezol (2.5 
mg/kg bodyweight) and Flumazenil (0.5 mg/kg bodyweight) in 0.9% NaCl.  
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5.3.2 Stab wound injury 
After verification of successful anesthesia, the fur on top of the skull was shaved using an 
electric razor. Mice were immobilized in a sterotactic apparatus and the skull was exposed 
with a cut of the integument. The skull was opened with a dental drill, above the 
somatosensory cortex and the right cortical hemisphere was subjected to a 0.5 mm deep and 
1mm long stab wound injury using a microblade. The wound was closed using a mono- 
filament and three stitches.  
5.3.3 Injection 
Three days post injury the mice were anaesthetized and immobilized as described above. 
Viral particles (300µl total volume) were injected into the center of the injury side (0.5 mm 
deep) using a pulled glass pipette and a positive displacement pump. Particles were injected 
with 30 nl/min in short start/stop intervals (5s injection – 5s pause). Subsequently the wound 
was closed using a mono- filament and three stitches.  
5.3.4 Perfusion and Fixation 
Animals were anaesthetized by injection of Ketamin and transcardially perfused with PBS 
followed by 4% paraformaldehyde. Brains were then isolated and fixed in 4% PFA at 4°C 
overnight, washed with and then stored in PBS.  
5.3.5 Preparation of brain slices 
To prevent ice crystals from breaking cell membranes, brains were cryoprotected. Brains were 
transferred to 15 ml tubes with 30% (w/v) sucrose in PBS and incubated at 4°C until the 
tissue sinks.  
Brains were then cut into 70 µm floating sections at the cryostat with a chamber temperature 
of 4°C, an object head temperature of -35°C and -10°C while cutting. Sliced were stored in 
storing solution at -20°C. 
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5fC  C5-formylcytosine 
5hmC  C5- hydroxymethylcytosine 
3mC  N3- methylcytosine 
5mC  5- methylcytosine 
AA  amino acid 
Ab  antibody 
bp  basepair 
C- terminal carboxy- terminal  
CRISPR clustered regularly interspaced short palindromic repeat  
dCas9  deadCas9 
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DNA  desoxy- ribonucleic acid 
DTT  dithiothreitol  
FACS  fluorescence activated cell sorting 
Fig  Figure  
E. coli  Escherichia coli 
g  gram  
gRNA  guideRNA 
h  hour or human  
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HEPES 4‐ (2‐ hydroxyethyl)‐1-piperazineethanesulfonic acid 
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kb  kilobases 
L2K  Lipofectamin 2000 
l  liter  
LB  lysogeny broth 
µ  micro- 
m  milli- 
min  minute 
MOI   multiplicity of infection 
n  nano 
NGS  normal goat serum or Next Generation Sequencing  
N- terminal amino- terminal 
OD  optical density  
PAM  protospacer adjacent motif 
PBS  phosphate buffered saline 
s  second  
TBS  Tris- buffered saline 
TBS- T TBS + Tween 
TSS  Transcription Start Site 
Tris  2- Amino- 2- hydroxymethyl- propane- 1, 3- diol 
U  units 
V  Volt 
v/v  volume per volume 
w/v  weight per volume 
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